Cadherin-11 inhibitors and methods of use thereof

ABSTRACT

Cadherin-11 inhibitors and methods for the prevention and treatment of cadherin-11 related diseases are described herein. Cadherin-11 related diseases include cancer and rheumatoid arthritis.

CROSS-REFERENCE TO PRIORITY APPLICATIONS

This application is a continuation of U.S. application Ser. No.14/323,374, filed Jul. 3, 2014, which is currently pending and which isa continuation of U.S. application Ser. No. 13/148,579, filed Feb. 8,2012, now issued U.S. Pat. No. 8,802,687, which is a U.S. national stagefiling of PCT/US10/23556, filed Feb. 9, 2010, which claims priority toU.S. Provisional Application No. 61/151,038, filed Feb. 9, 2009. Theseapplications are incorporated by reference herein in their entireties.

STATEMENT REGARDING FEDERALLY FUNDED RESEARCH

This invention was made with government support under Grant No. DODBC062416-01 awarded by the Department of Defense. The government hascertain rights in the invention.

BACKGROUND

Advanced epithelial cancers, such as those of the prostate and breast,often exhibit morphologic and molecular changes characteristic ofmesenchymal tissue. Breast cancer progression to an invasive metastaticstate is hypothesized to represent a form of epithelial-mesenchymaltransition (EMT), a process of profound importance during embryogenesis.A process referred to as “cadherin-switching” involves an increasedexpression of mesenchymal cadherins (often N-cadherin or cadherin-11) inconjunction with down-regulation of epithelial markers (E-cadherin), andis associated with both EMT and tumor progression. Cadherin-11, notnormally expressed in normal epithelium, is found in prostate and breastcancer lymph node and bone metastases and its expression directlycorrelates to disease progression.

SUMMARY

Provided herein are compounds and methods for the prevention andtreatment of cadherin-11 related diseases, including cancer andrheumatoid arthritis. A class of compounds for use in the methodsdescribed herein includes compounds of the following formula:

and pharmaceutically acceptable salts and prodrugs thereof. In thesecompounds, R⁴, R⁵, R⁶, R⁹, R¹⁰, and R¹¹ are each independently selectedfrom hydrogen, halogen, hydroxyl, substituted or unsubstituted alkoxy,substituted or unsubstituted amido, substituted or unsubstituted amino,substituted or unsubstituted carbonyl, substituted or unsubstitutedalkyl, unsubstituted or unsubstituted alkenyl, substituted orunsubstituted alkynyl, unsubstituted heteroalkyl, unsubstituted orunsubstituted heteroalkenyl, substituted or unsubstituted heteroalkynyl,substituted or unsubstituted cycloalkyl, unsubstituted or unsubstitutedcycloalkenyl, substituted or unsubstituted cycloalkynyl, substituted orunsubstituted heterocycloalkyl, unsubstituted or unsubstitutedheterocycloalkenyl, substituted or unsubstituted heterocycloalkynyl,substituted or unsubstituted aryl, or substituted or unsubstitutedheteroaryl; and R¹³ is halogen, hydroxyl, substituted or unsubstitutedalkoxy, substituted or unsubstituted amido, substituted or unsubstitutedamino, substituted or unsubstituted carbonyl, substituted orunsubstituted alkyl, unsubstituted or unsubstituted alkenyl, substitutedor unsubstituted alkynyl, unsubstituted heteroalkyl, unsubstituted orunsubstituted heteroalkenyl, substituted or unsubstituted heteroalkynyl,substituted or unsubstituted cycloalkyl, unsubstituted or unsubstitutedcycloalkenyl, substituted or unsubstituted cycloalkynyl, substituted orunsubstituted heterocycloalkyl, unsubstituted or unsubstitutedheterocycloalkenyl, substituted or unsubstituted heterocycloalkynyl,substituted or unsubstituted aryl, or substituted or unsubstitutedheteroaryl. In some examples, R⁵ is hydroxyl. In some examples, R¹⁰ ishydroxyl. In some examples, R⁶ is chloro. In some examples, R¹³ ishydroxyl, chloro, or carboxyl.

Also described herein are compounds of the following formulas:

or a pharmaceutically acceptable salt or prodrug thereof.

Also provided herein are compositions including a compound as describedabove and a pharmaceutically acceptable carrier. Kits, including acompound or composition as described herein, are also provided.

Further provided herein are methods of preventing or treating acadherin-11 related disease in a subject. Examples of cadherin-11related diseases include rheumatoid arthritis and cancer (e.g., breastcancer (including basal-like cancer), prostate cancer, glioma,glioblastoma, myeloma, leukemia, poor prognosis/invasive cancer,mesenchymal-like cancer, and metastatic cancer). A method of preventingor treating a cadherin-11 related disease in a subject includesadministering to the subject an effective amount of a compound of thefollowing formula:

or a pharmaceutically acceptable salt or prodrug thereof. In thismethod, R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, R⁹, R¹⁰, R¹¹, and R¹² are eachindependently selected from hydrogen, halogen, hydroxyl, substituted orunsubstituted alkoxy, substituted or unsubstituted amido, substituted orunsubstituted amino, substituted or unsubstituted carbonyl, substitutedor unsubstituted alkyl, unsubstituted or unsubstituted alkenyl,substituted or unsubstituted alkynyl, unsubstituted heteroalkyl,unsubstituted or unsubstituted heteroalkenyl, substituted orunsubstituted heteroalkynyl, substituted or unsubstituted cycloalkyl,unsubstituted or unsubstituted cycloalkenyl, substituted orunsubstituted cycloalkynyl, substituted or unsubstitutedheterocycloalkyl, unsubstituted or unsubstituted heterocycloalkenyl,substituted or unsubstituted heterocycloalkynyl, substituted orunsubstituted aryl, or substituted or unsubstituted heteroaryl; and X¹and X² are each independently selected from CH or N. In some examples,R¹ and R² are combined to form a substituted or unsubstituted aryl,substituted or unsubstituted heteroaryl, substituted or unsubstitutedcycloalkyl, substituted or unsubstituted cycloalkenyl, substituted orunsubstituted cycloalkynyl, substituted or unsubstitutedheterocycloalkyl, substituted or unsubstituted heterocycloalkenyl, orsubstituted or unsubstituted heterocycloalkynyl.

A method of preventing or treating a cadherin-11 related disease in asubject includes administering to the subject an effective amount of acompound of the following formula:

or a pharmaceutically acceptable salt or prodrug thereof. In thismethod, R⁵ and R¹⁰ are each independently selected from hydrogen,halogen, hydroxyl, substituted or unsubstituted alkoxy, substituted orunsubstituted amido, substituted or unsubstituted amino, substituted orunsubstituted carbonyl, substituted or unsubstituted alkyl,unsubstituted or unsubstituted alkenyl, substituted or unsubstitutedalkynyl, unsubstituted heteroalkyl, unsubstituted or unsubstitutedheteroalkenyl, substituted or unsubstituted heteroalkynyl, substitutedor unsubstituted cycloalkyl, unsubstituted or unsubstitutedcycloalkenyl, substituted or unsubstituted cycloalkynyl, substituted orunsubstituted heterocycloalkyl, unsubstituted or unsubstitutedheterocycloalkenyl, substituted or unsubstituted heterocycloalkynyl,substituted or unsubstituted aryl, or substituted or unsubstitutedheteroaryl; and X is selected from CH or N. For example, the compoundcan be:

or a pharmaceutically acceptable salt or prodrug thereof.

A method of preventing or treating a cadherin-11 related disease in asubject includes administering to the subject an effective amount of acompound of the following formula:

or a pharmaceutically acceptable salt or prodrug thereof. In thismethod, R⁴, R⁵, R⁶, R⁹, R¹⁰, R¹¹, and R¹³ are each independentlyselected from hydrogen, halogen, hydroxyl, substituted or unsubstitutedalkoxy, substituted or unsubstituted amido, substituted or unsubstitutedamino, substituted or unsubstituted carbonyl, substituted orunsubstituted alkyl, unsubstituted or unsubstituted alkenyl, substitutedor unsubstituted alkynyl, unsubstituted heteroalkyl, unsubstituted orunsubstituted heteroalkenyl, substituted or unsubstituted heteroalkynyl,substituted or unsubstituted cycloalkyl, unsubstituted or unsubstitutedcycloalkenyl, substituted or unsubstituted cycloalkynyl, substituted orunsubstituted heterocycloalkyl, unsubstituted or unsubstitutedheterocycloalkenyl, substituted or unsubstituted heterocycloalkynyl,substituted or unsubstituted aryl, or substituted or unsubstitutedheteroaryl. In some examples, R⁵ is hydroxyl. In some examples, R¹⁰ ishydroxyl. In some examples, R⁶ is chloro. In some examples, R¹³ ishydroxyl, chloro, or carboxyl. Further examples of the compounds for usein these methods include:

or pharmaceutically acceptable salts or prodrugs thereof.

A method of preventing or treating a cadherin-11 related disease in asubject includes administering to the subject an effective amount of acompound of the following formula:

or a pharmaceutically acceptable salt or prodrug thereof. In thismethod, R¹, R², R³, R⁴, and R⁵ are each independently selected fromhydrogen, halogen, hydroxyl, substituted or unsubstituted alkoxy,substituted or unsubstituted amido, substituted or unsubstituted amino,substituted or unsubstituted carbonyl, substituted or unsubstitutedalkyl, unsubstituted or unsubstituted alkenyl, substituted orunsubstituted alkynyl, unsubstituted heteroalkyl, unsubstituted orunsubstituted heteroalkenyl, substituted or unsubstituted heteroalkynyl,substituted or unsubstituted cycloalkyl, unsubstituted or unsubstitutedcycloalkenyl, substituted or unsubstituted cycloalkynyl, substituted orunsubstituted heterocycloalkyl, unsubstituted or unsubstitutedheterocycloalkenyl, substituted or unsubstituted heterocycloalkynyl,substituted or unsubstituted aryl, or substituted or unsubstitutedheteroaryl. In some examples, one or more of R¹ and R², R² and R³, or R³and R⁴ are combined to form a substituted or unsubstituted aryl,substituted or unsubstituted heteroaryl, substituted or unsubstitutedcycloalkyl, substituted or unsubstituted cycloalkenyl, substituted orunsubstituted cycloalkynyl, substituted or unsubstitutedheterocycloalkyl, substituted or unsubstituted heterocycloalkenyl, orsubstituted or unsubstituted heterocycloalkynyl. Examples of compoundsfor use in these methods include:

or pharmaceutically acceptable salts or prodrugs thereof.

The methods of preventing or treating a cadherin-11 related disease in asubject as described herein can further include administering a secondtherapeutic agent to the subject. Examples of second therapeutic agentsinclude chemotherapeutic agents and anti-inflammatory agents.

Further provided are methods of preventing or treating cancer in asubject including selecting a subject with a poor prognosis/invasivecancer and administering to the subject a cadherin-11 inhibitor. Methodsof inhibiting tumor growth, invasion, or metastasis in a subjectcomprising administering to the subject a cadherin-11 inhibitor are alsoincluded. The cadherin-11 inhibitor can be, for example, an antibody.

The details of one or more examples of the compounds and methods are setforth in the accompanying drawings and the description below. Otherfeatures, objects, and advantages will be apparent from the descriptionand drawings, and from the claims.

DESCRIPTION OF DRAWINGS

FIG. 1A is a schematic showing the EC1 homodimer of cadherin-11 with P1and P2 binding pockets.

FIG. 1B is a schematic showing the EC1 homodimer interface ofcadherin-11.

FIG. 2 shows images of the inhibition of cadherin-11 expression withRNAi in transient and pooled stables. Two independently derivedcadherin-11 siRNA (6A, 4A) lines; control pooled stable cell line from ascrambled construct (1B).

FIG. 3 is a bar graph showing the percent growth of untreated cells andcells treated with Compound 1 at concentrations of 100 nM, 300 nM, and800 nM after five days.

FIG. 4 shows pictures of untreated cells (231) and cells treated with100 nM of Compound 1 (231+100 nM) after two and six days.

FIG. 5 is a bar graph showing the cell growth of untreated cells (231)and cells treating with 100 nM of Compound 1 (231+100 nM) after fivedays as measured by chemoluminescence.

FIG. 6A shows pictures of colonies of untreated cells (231) and cellstreated with 100 nM of Compound 1 (231+sd-133 (100 nM)).

FIG. 6B is a bar graph showing the total average number of colonies inuntreated cells (231) and cells treated with 100 nM of Compound 1(231+100 nM).

FIG. 7 is a bar graph showing the colony and size of the colony foruntreated cells (231) and cells treated with 100 nM of Compound 1(231+100 nM).

FIG. 8 shows graphs displaying the tumor growth in nude mice injectedwith cells expressing control siRNA (RNAi 1B) and cadherin-11 siRNA(RNAi 6A and RNAi 4A).

FIG. 9A is a schematic of the small molecule screening strategydescribed in the examples below.

FIG. 9B is a schematic of the structural model of Compound 1 withcadherin-11.

FIGS. 10A-C show graphs of Kaplan-Meier survival curves showing thecorrelation of cadherin-11 (CDH11) expression with clinical outcome inpoor prognosis cancers. Kaplan-Meier survival curves of breast (A),prostate (B), and glioblastoma (C) patients (log-rank test p<0.05) areprovided.

FIG. 11A is a Western blot of cadherin-11 (CDH11) in MDA-MB-231 cellsstably expressing cadherin-11 shRNA (33 or 34 clonal cells) or siRNA (4Aor 6A pooled cell lines), and PC-3 cells containing the same shRNA,along with empty vector (EV or 1B, respectively) or scrambled (Luc)controls. GAPDH was used as a loading control.

FIG. 11B is a graph showing the effect of cadherin-11 depletion onproliferation on shRNA, siRNA, and PC-3 cells measured using crystalviolet staining after 5 days.

FIG. 11C is a graph showing the effect of cadherin-11 depletion onanchorage-independent colony formation in soft agar and also phaseimages of colony formation using a 4× objective on a Zeiss invertedmicroscope. Columns and bars show the mean and SEM, respectively.

FIG. 12A shows bar graphs demonstrating that cadherin-11 depletionsignificantly reduces the migration of stable cells into wounds asmeasured by time-lapse imaging from three separate fields (triplicatewells, 24-well plate) 16 hours after wounding. Columns and bars show themean and SEM, respectively.

FIG. 12B shows pictures that show cadherin-11 depletion delays formationof branched networks on Matrigel.

FIG. 13A shows graphs displaying the tumor volume in athymic nude miceinjected s.c. with MDA-MB-231 cells stably expressing cadherin-11 siRNAor shRNA. The tumor volume was measured 2× per week for at least 40days.

FIG. 13B shows Kaplan-Meier analysis log-rank test (p<0.001) of tumorincidence/latency of MDA-MB-231 cells in nude mice.

FIG. 14A is a flowchart depicting microarray analysis of pooled celllines [3 controls (1B), 2 each of 4A and 6A knockdown cells] done with asignificance of p<0.01 (See Materials and Methods).

FIG. 14B shows a hierarchical cluster analysis between control andknockdown probes resulted in 187 cadherin-11 (CDH11)-regulated genes.

FIG. 14C shows a subset of 24 cadherin-11 (CDH11)-regulated genesassociated with clinical outcome in human breast cancer relapse.

FIG. 15A is a graph showing the cell growth of MDA-MB-231, caherin-11(CDH11)-negative MDA-MB-435 melanoma, and MCF7 breast cancer cell linesafter treatment with Compound 1.

FIG. 15B, left panel, shows pictures of MDA-MB-231 cells untreated(231), treated with Compound 9 (231+100 nM (Sd-037)), and treated withCompound 1 (231+100 nM (Sd-133)) after two and six days. The right panelshows pictures of MDA-MB-435 and MCF7 cells untreated (MDA-435 andMCF7), treated with 1 Compound 1 (+1 μM Sd-133), and treated with 10 μMCompound 1 (+10 μM Sd-133) after three and six days

FIG. 15C, left panel, shows a bar graph showing the cell growth ofuntreated MDA-MB-231 cells (231) and cells treated with 100 nM ofCompound 1 (231+100 nM Sd-133) and the corresponding pictures of thecells. The middle panel is a bar graph showing the colony number andsize of the colony for untreated cells (231+DMSO) and cells treated with100 nM of Compound 1 (231+Sd-133(100 nM)). The right panel shows a bargraph showing the cell growth of untreated MDA-435 or MCF7 cells andcells treated with 100 nM of Compound 1 (+100 nM Sd-133) and thecorresponding pictures of the cells.

FIGS. 16A and B are graphs showing the cell aggregation for cells withempty vectors or cells with stably-transfected cadherin-11. The cellswere either untreated, treated with EDTA (0.5 mM, 0.25 mM, or 0.1 mM),treated with 1 μM of Compound 1 (Sd-133), treated with 1 μM of Compound2 (Sd-133A), treated with 1 μM of Compound 3 (Sd-133B), treated with 1TM of Compound 11 (Sd-12), treated with 1 TM of Compound 12 (Sd-48),treated with 1 TM of Compound 17 (Sd-20), treated with 1 TM of Compound18 (Sd-51), treated with 1 TM of Compound 19 (Sd-22), or treated with 1TM of Compound 20 (Sd-23).

FIG. 17A shows pictures of cells expressing cadherin-11 or beta-catenin.

FIG. 17B shows graphs of the effect of cadherin-11 depletion onproliferation of cells.

FIG. 17C shows graphs of the effect of cadherin-11 depletion onanchorage-independent colony growth of cells.

FIG. 18A shows images of the inhibition of cadherin-11 and N-cadherinexpression with lentivirus containing shRNA in glioblastoma cell lineLN229.

FIG. 18B is a graph showing the relative migration of control LN229 celllines (LN229 pLKO) and cell lines with inhibited expression ofcadherin-11 (LN229 cad 11 #36).

FIG. 18C is a graph showing the cell proliferation of control LN229 celllines (LN229 pLKO) and cell lines with inhibited expression ofcadherin-11 (LN229 Cad11#36 and LN229 Cad11#34).

DETAILED DESCRIPTION

Epithelial-to-mesenchymal transition (EMT) occurs in malignanttransformation and progression. Aggressive cancer cell lines ofepithelial origin often appear morphologically similar to mesenchymalcells and generally express various mesenchymal markers. Cadherin-11expression in breast and prostate cancers represents a form of EMT thatthe cells utilize to progress and metastasize. Cadherin switching, aphenomenon characterized by down-regulation of the normally-expressedepithelial cadherin concomitant with upregulation of a mesenchymalcadherin, has been observed in various epithelial malignancies,including breast and prostate cancers.

To date, there are few viable treatment options for aggressive,basal-like cancers and/or distant metastasis in breast or prostatecancer. The examples described herein indicate that expression ofcadherin-11 in cancer may be indicative of a more aggressive, basal-likecancer that would require specific therapeutics. The cadherin-11inhibitors described herein block the proliferative and invasivefunctions of cadherin-11 in aggressive cancer cells. To identifycadherin-11-specific EC1 domain inhibitors, the EC1 domain ofcadherin-11 and N-cadherin were compared. Several important differenceswere revealed, including the fact that cadherin-11 has a largerhydrophobic cleft than N-cadherin, and two Trp residues in cadherin-11,rather than one in N-cadherin, anchor the EC1 homodimer interface.Generally, the cadherin-11 accessible surface area is also larger thanthat of N-cadherin, indicating that there may be more opportunity fortargeting than in the type 1 cadherins. The compounds described hereinare readily soluble in DMSO, surpassing the hurdle of hydrophobicity,and are exceptionally potent at nanomolar concentrations, which mayindicate solid potential for a targeted therapy that displays inherentlow toxicity in patients.

Aggressive breast and prostate cancer cells, MDA-MB-231 and PC-3 cellsrespectively, preferentially metastasize to the skeleton followingintracardiac injection in nude mice. As described in the examples below,depletion of cadherin-11 in PC-3 prostate cancer cells results in agreatly reduced ability to adhere to cadherin-11 in vitro and formskeletal metastases in vivo. As also described in the examples below,primary tumor growth could be prevented upon virtual deletion ofcadherin-11 in aggressive MDA-MB-231 breast cancer cells, demonstratingthe critical role cadherin-11 plays in tumorigenesis of breast andprostate cancers that express it. The examples described herein showthat the reduction of cadherin-11 significantly inhibits proliferation,migration, and invasion of epithelial cancer cells. Further, theexamples illustrate that cadherin-11 depletion eliminates tumorigenicpotential in vivo. Validation of this result was shown by re-expressionof cadherin-11 in the cells, which reverses all observed phenotypes.

Described herein are compounds for use as cadherin-11 inhibitors andmethods for the prevention and treatment of cadherin-11 relateddiseases, including cancer and rheumatoid arthritis. Examples of cancertypes include, but are not limited to, renal cell cancer, prostatecancer, breast cancer, glioma, glioblastoma, myeloma, and leukemia.Optionally, the cancer exhibits morphologic and molecular changescharacteristic of mesenchymal tissue (i.e., mesenchymal-like cancer) orhas a basal-like phenotype (i.e., a basal-like cancer). Optionally, thecancer is metastatic or has a poor prognosis.

The method of preventing or treating a cadherin-11 related disease asdescribed herein includes administering to a subject a cadherin-11inhibitor. Such inhibitors are administered in an effective amount toprevent or treat one or more symptoms of the cadherin-11 relateddisease.

A class of cadherin-11 inhibitors includes compounds represented byFormula I:

or a pharmaceutically acceptable salt or prodrug thereof.

In Formula I, R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, R⁹, R¹⁰, R¹¹, and R¹² areeach independently selected from hydrogen, halogen, hydroxyl,substituted or unsubstituted alkoxy, substituted or unsubstituted amido,substituted or unsubstituted amino, substituted or unsubstitutedcarbonyl, substituted or unsubstituted alkyl, unsubstituted orunsubstituted alkenyl, substituted or unsubstituted alkynyl,unsubstituted heteroalkyl, unsubstituted or unsubstituted heteroalkenyl,substituted or unsubstituted heteroalkynyl, substituted or unsubstitutedcycloalkyl, unsubstituted or unsubstituted cycloalkenyl, substituted orunsubstituted cycloalkynyl, substituted or unsubstitutedheterocycloalkyl, unsubstituted or unsubstituted heterocycloalkenyl,substituted or unsubstituted heterocycloalkynyl, substituted orunsubstituted aryl, or substituted or unsubstituted heteroaryl.

Also in Formula I, X¹ and X² are each independently selected from CH orN.

In Formula I, R¹ and R² are optionally combined to form a substituted orunsubstituted aryl, substituted or unsubstituted heteroaryl, substitutedor unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl,substituted or unsubstituted cycloalkynyl, substituted or unsubstitutedheterocycloalkyl, substituted or unsubstituted heterocycloalkenyl, orsubstituted or unsubstituted heterocycloalkynyl.

Examples of Formula I include compounds represented by Formula I-A:

and pharmaceutically acceptable salts and prodrugs thereof.

In Formula I-A, R⁵ and R¹⁰ are each independently selected fromhydrogen, halogen, hydroxyl, substituted or unsubstituted alkoxy,substituted or unsubstituted amido, substituted or unsubstituted amino,substituted or unsubstituted carbonyl, substituted or unsubstitutedalkyl, unsubstituted or unsubstituted alkenyl, substituted orunsubstituted alkynyl, unsubstituted heteroalkyl, unsubstituted orunsubstituted heteroalkenyl, substituted or unsubstituted heteroalkynyl,substituted or unsubstituted cycloalkyl, unsubstituted or unsubstitutedcycloalkenyl, substituted or unsubstituted cycloalkynyl, substituted orunsubstituted heterocycloalkyl, unsubstituted or unsubstitutedheterocycloalkenyl, substituted or unsubstituted heterocycloalkynyl,substituted or unsubstituted aryl, or substituted or unsubstitutedheteroaryl.

Also in Formula I-A, X is selected from CH or N.

An example of Formula I-A includes the following Compound 1.

Formula I also includes compounds represented by Formula I-B:

or a pharmaceutically acceptable salt or prodrug thereof.

In Formula I-B, R⁴, R⁵, R⁶, R⁹, R¹⁰, R¹¹, and R¹³ are each independentlyselected from hydrogen, halogen, hydroxyl, substituted or unsubstitutedalkoxy, substituted or unsubstituted amido, substituted or unsubstitutedamino, substituted or unsubstituted carbonyl, substituted orunsubstituted alkyl, unsubstituted or unsubstituted alkenyl, substitutedor unsubstituted alkynyl, unsubstituted heteroalkyl, unsubstituted orunsubstituted heteroalkenyl, substituted or unsubstituted heteroalkynyl,substituted or unsubstituted cycloalkyl, unsubstituted or unsubstitutedcycloalkenyl, substituted or unsubstituted cycloalkynyl, substituted orunsubstituted heterocycloalkyl, unsubstituted or unsubstitutedheterocycloalkenyl, substituted or unsubstituted heterocycloalkynyl,substituted or unsubstituted aryl, or substituted or unsubstitutedheteroaryl. In Formula I-B, R⁵ is optionally hydroxyl. In Formula I-B,R⁶ is optionally chloro. In Formula I-B, R¹⁰ is optionally hydroxyl. InFormula I-B, R¹³ is optionally hydroxyl, chloro, or carboxyl. In FormulaI-B, R¹³ is optionally not hydroxyl.

Examples of Formula I-B include, but are not limited to, the followingcompounds:

A class of cadherin-11 inhibitors useful in the methods described hereinis represented by Formula II:

or a pharmaceutically acceptable salt or prodrug thereof.

In Formula II, R¹, R², R³, R⁴, and R⁵ are each independently selectedfrom hydrogen, halogen, hydroxyl, substituted or unsubstituted alkoxy,substituted or unsubstituted amido, substituted or unsubstituted amino,substituted or unsubstituted carbonyl, substituted or unsubstitutedalkyl, unsubstituted or unsubstituted alkenyl, substituted orunsubstituted alkynyl, unsubstituted heteroalkyl, unsubstituted orunsubstituted heteroalkenyl, substituted or unsubstituted heteroalkynyl,substituted or unsubstituted cycloalkyl, unsubstituted or unsubstitutedcycloalkenyl, substituted or unsubstituted cycloalkynyl, substituted orunsubstituted heterocycloalkyl, unsubstituted or unsubstitutedheterocycloalkenyl, substituted or unsubstituted heterocycloalkynyl,substituted or unsubstituted aryl, or substituted or unsubstitutedheteroaryl.

In Formula II, adjacent R groups on the phenyl ring, i.e., R¹, R², R³,and R⁴, can be combined to form substituted or unsubstituted aryl,substituted or unsubstituted heteroaryl, substituted or unsubstitutedcycloalkyl, substituted or unsubstituted cycloalkenyl, substituted orunsubstituted cycloalkynyl, substituted or unsubstitutedheterocycloalkyl, substituted or unsubstituted heterocycloalkenyl, orsubstituted or unsubstituted heterocycloalkynyl groups. For example, R¹can be a ethylene group and R² can be an methanimine group that combineto form a C₆ heteroaryl. Other adjacent R groups include thecombinations of R² and R³, and R³ and R⁴.

Examples of Formula II include, but are not limited to:

Additional cadherin-11 inhibitors useful in the methods described hereinhave also been identified that may not be represented by Formula I orFormula II. The structures of these cadherin-11 inhibitors are asfollows:

As used herein, the terms alkyl, alkenyl, and alkynyl include straight-and branched-chain monovalent substituents. Examples include methyl,ethyl, isobutyl, 3-butynyl, and the like. Ranges of these groups usefulwith the compounds and methods described herein include C₁-C₂₀ alkyl,C₂-C₂₀ alkenyl, and C₂-C₂₀ alkynyl. Additional ranges of these groupsuseful with the compounds and methods described herein include C₁-C₁₂alkyl, C₂-C₁₂ alkenyl, C₂-C₁₂ alkynyl, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆alkynyl, C₁-C₄ alkyl, C₂-C₄ alkenyl, and C₂-C₄ alkynyl.

Heteroalkyl, heteroalkenyl, and heteroalkynyl are defined similarly asalkyl, alkenyl, and alkynyl, but can contain O, S, or N heteroatoms orcombinations thereof within the backbone. Ranges of these groups usefulwith the compounds and methods described herein include C₁-C₂₀heteroalkyl, C₂-C₂₀ heteroalkenyl, and C₂-C₂₀ heteroalkynyl. Additionalranges of these groups useful with the compounds and methods describedherein include C₁-C₁₂ heteroalkyl, C₂-C₁₂ heteroalkenyl, C₂-C₁₂heteroalkynyl, C₁-C₆ heteroalkyl, C₂-C₆ heteroalkenyl, C₂-C₆heteroalkynyl, C₁-C₄ heteroalkyl, C₂-C₄ heteroalkenyl, and C₂-C₄heteroalkynyl.

The terms cycloalkyl, cycloalkenyl, and cycloalkynyl include cyclicalkyl groups having a single cyclic ring or multiple condensed rings.Examples include cyclohexyl, cyclopentylethyl, and adamantanyl. Rangesof these groups useful with the compounds and methods described hereininclude C₃-C₂₀ cycloalkyl, C₃-C₂₀ cycloalkenyl, and C₃-C₂₀ cycloalkynyl.Additional ranges of these groups useful with the compounds and methodsdescribed herein include C₅-C₁₂ cycloalkyl, C₅-C₁₂ cycloalkenyl, C₅-C₁₂cycloalkynyl, C₅-C₆ cycloalkyl, C₅-C₆ cycloalkenyl, and C₅-C₆cycloalkynyl.

The terms heterocycloalkyl, heterocycloalkenyl, and heterocycloalkynylare defined similarly as cycloalkyl, cycloalkenyl, and cycloalkynyl, butcan contain O, S, or N heteroatoms or combinations thereof within thecyclic backbone. Ranges of these groups useful with the compounds andmethods described herein include C₃-C₂₀ heterocycloalkyl, C₃-C₂₀heterocycloalkenyl, and C₃-C₂₀ heterocycloalkynyl. Additional ranges ofthese groups useful with the compounds and methods described hereininclude C₅-C₁₂ heterocycloalkyl, C₅-C₁₂ heterocycloalkenyl, C₅-C₁₂heterocycloalkynyl, C₅-C₆ heterocycloalkyl, C₅-C₆ heterocycloalkenyl,and C₅-C₆ heterocycloalkynyl.

Aryl molecules include, for example, cyclic hydrocarbons thatincorporate one or more planar sets of, typically, six carbon atoms thatare connected by delocalized electrons numbering the same as if theyconsisted of alternating single and double covalent bonds. An example ofan aryl molecule is benzene. Heteroaryl molecules include substitutionsalong their main cyclic chain of atoms such as O, N, or S. Whenheteroatoms are introduced, a set of five atoms, e.g., four carbon and aheteroatom, can create an aromatic system. Examples of heteroarylmolecules include furan, pyrrole, thiophene, imadazole, oxazole,pyridine, and pyrazine. Aryl and heteroaryl molecules can also includeadditional fused rings, for example, benzofuran, indole, benzothiophene,naphthalene, anthracene, and quinoline.

The alkyl, alkenyl, alkynyl, aryl, heteroalkyl, heteroalkenyl,heteroalkynyl, heteroaryl, cycloalkyl, cycloalkenyl, cycloalkynyl,heterocycloalkyl, heterocycloalkenyl, or heterocycloalkynyl moleculesused herein can be substituted or unsubstituted. As used herein, theterm substituted includes the addition of an alkyl, alkenyl, alkynyl,aryl, heteroalkyl, heteroalkenyl, heteroalkynyl, heteroaryl, cycloalkyl,cycloalkenyl, cycloalkynyl, heterocycloalkyl, heterocycloalkenyl, orheterocycloalkynyl group to a position attached to the main chain of thealkyl, alkenyl, alkynyl, aryl, heteroalkyl, heteroalkenyl,heteroalkynyl, heteroaryl, cycloalkyl, cycloalkenyl, cycloalkynyl,heterocycloalkyl, heterocycloalkenyl, or heterocycloalkynyl, e.g., thereplacement of a hydrogen by one of these molecules. Examples ofsubstitution groups include, but are not limited to, hydroxyl, halogen(e.g., F, Br, Cl, or I), and carboxyl groups. Conversely, as usedherein, the term unsubstituted indicates the alkyl, alkenyl, alkynyl,aryl, heteroalkyl, heteroalkenyl, heteroalkynyl, heteroaryl, cycloalkyl,cycloalkenyl, cycloalkynyl, heterocycloalkyl, heterocycloalkenyl, orheterocycloalkynyl has a full complement of hydrogens, i.e.,commensurate with its saturation level, with no substitutions, e.g.,linear decane (—(CH₂)₉—CH₃).

The compounds described herein can be prepared in a variety of ways. Thecompounds can be synthesized using various synthetic methods. At leastsome of these methods are known in the art of synthetic organicchemistry. The compounds described herein can be prepared from readilyavailable starting materials. Optimum reaction conditions can vary withthe particular reactants or solvent used, but such conditions can bedetermined by one skilled in the art by routine optimization procedures.

Variations on Formula I, Formula II, and the additional cadherin-11inhibitors described above include the addition, subtraction, ormovement of the various constituents as described for each compound.Similarly, when one or more chiral centers are present in a molecule,the chirality of the molecule can be changed. Additionally, compoundsynthesis can involve the protection and deprotection of variouschemical groups. The use of protection and deprotection, and theselection of appropriate protecting groups can be determined by oneskilled in the art. The chemistry of protecting groups can be found, forexample, in Greene, et al., Protective Groups in Organic Synthesis, 2d.Ed., Wiley & Sons, 1991, which is incorporated herein by reference inits entirety.

Reactions to produce the compounds described herein can be carried outin solvents, which can be selected by one of skill in the art of organicsynthesis. Solvents can be substantially nonreactive with the startingmaterials (reactants), the intermediates, or products under theconditions at which the reactions are carried out, i.e., temperature andpressure. Reactions can be carried out in one solvent or a mixture ofmore than one solvent. Product or intermediate formation can bemonitored according to any suitable method known in the art. Forexample, product formation can be monitored by spectroscopic means, suchas nuclear magnetic resonance spectroscopy (e.g., ¹H or ¹³C) infraredspectroscopy, spectrophotometry (e.g., UV-visible), or massspectrometry, or by chromatography such as high performance liquidchromatography (HPLC) or thin layer chromatography.

Optionally, in the provided methods the cadherin-11 inhibitor is anantibody. Such antibodies are described, for example, in Valencia etal., J. Exp. Med., 200(12):1673-1679 (2004) and Kiener et al., Arthritis& Rheumatism, 60(5):1305-1310 (2009), which are incorporated herein bytheir reference at least for the antibodies and methods of making theantibodies. Such antibodies include, but are not limited to,cadherin-11-2G4, cadherin-11-3H10, and cadherin-11-5H6. These antibodiescan be modified as described in more detail below. For example, theseantibodies can be modified to produce fragments or chimeric or humanizedversions of the antibodies.

Provided is a method of preventing or treating a cadherin-11 relateddisease in a subject comprising administering to the subject an antibodyto cadherin-11. Optionally, as described below the cadherin-11 relateddisease is cancer. Methods of inhibiting tumor growth, invasion, ormetastasis in a subject comprising administering a cadherin-11 inhibitor(e.g., an antibody) is also provided.

As used herein, the term antibody encompasses, but is not limited to,whole immunoglobulin (i.e., an intact antibody) of any class. The termantibody or fragments thereof can also encompass chimeric antibodies andhybrid antibodies, with dual or multiple antigen or epitopespecificities, and fragments, such as F(ab′)2, Fab′, Fab and the like,including hybrid fragments. Thus, fragments of the antibodies thatretain the ability to bind their specific antigens are provided. Forexample, fragments of antibodies that bind cadherin-11 are includedwithin the meaning of the term antibody or fragment thereof. Suchantibodies and fragments can be made by techniques known in the art andcan be screened for specificity and activity according to the methodsset forth in the Examples and in general methods for producingantibodies and screening antibodies for specificity and activity (SeeHarlow and Lane. Antibodies, A Laboratory Manual. Cold Spring HarborPublications, New York, (1988)).

Also included within the meaning of antibody or fragments thereof areconjugates of antibody fragments and antigen binding proteins (singlechain antibodies) as described, for example, in U.S. Pat. No. 4,704,692,the contents of which are hereby incorporated by reference in theirentirety.

Optionally, the antibody is a monoclonal antibody. The term monoclonalantibody as used herein refers to an antibody obtained from asubstantially homogeneous population of antibodies, i.e., the individualantibodies comprising the population are identical except for possiblenaturally occurring mutations that may be present in minor amounts. Themonoclonal antibodies herein specifically include chimeric antibodies inwhich a portion of the heavy and/or light chain is identical with orhomologous to corresponding sequences in antibodies derived from aparticular species or belonging to a particular antibody class orsubclass, while the remainder of the chain(s) is identical with orhomologous to corresponding sequences in antibodies derived from anotherspecies or belonging to another antibody class or subclass, as well asfragments of such antibodies, so long as they exhibit the desiredactivity (See, U.S. Pat. No. 4,816,567 and Morrison et al., PNAS,81:6851-6855 (1984)).

Monoclonal antibodies may be prepared using hybridoma methods, such asthose described by Kohler and Milstein, Nature, 256:495 (1975) or Harlowand Lane, Antibodies, A Laboratory Manual. Cold Spring HarborPublications, New York, (1988). In a hybridoma method, a mouse or otherappropriate host animal, is typically immunized with an immunizing agentto elicit lymphocytes that produce or are capable of producingantibodies that will specifically bind to the immunizing agent.Alternatively, the lymphocytes may be immunized in vitro. The immunizingagent can be a cadherin-11 or a fragment thereof.

The monoclonal antibodies may also be made by recombinant DNA methods,such as those described in U.S. Pat. No. 4,816,567. DNA encoding themonoclonal antibodies can be readily isolated and sequenced usingconventional procedures (e.g., by using oligonucleotide probes that arecapable of binding specifically to genes encoding the heavy and lightchains of murine antibodies). The hybridoma cells can serve as apreferred source of such DNA. Once isolated, the DNA may be placed intoexpression vectors, which are then transfected into host cells such assimian COS cells, Chinese hamster ovary (CHO) cells, plasmacytoma cells,or myeloma cells that do not otherwise produce immunoglobulin protein,to obtain the synthesis of monoclonal antibodies in the recombinant hostcells. The DNA also may be modified, for example, by substituting thecoding sequence for human heavy and light chain constant domains inplace of the homologous murine sequences (U.S. Pat. No. 4,816,567) or bycovalently joining to the immunoglobulin coding sequence all or part ofthe coding sequence for a non-immunoglobulin polypeptide. Such anon-immunoglobulin polypeptide can be substituted for the constantdomains of an antibody provided herein, or can be substituted for thevariable domains of one antigen-combining site of an antibody to createa chimeric bivalent antibody comprising one antigen-combining sitehaving specificity for cadherin-11 and another antigen-combining sitehaving specificity for a different antigen (e.g., a different cancerantigen).

Further provided herein is a humanized or human version of the antibody.Optionally, the antibody activates or inhibits cadherin-11. Optionally,the humanized or human antibody can comprise at least one residue of theframework region of the monoclonal antibody. Humanized and humanantibodies can be made using methods known to a skilled artesian; forexample, the human antibody can be produced using a germ-line mutantanimal or by a phage display library.

Antibodies can also be generated in other species and humanized foradministration to humans. Alternatively, fully human antibodies can alsobe made by immunizing a mouse or other species capable of making a fullyhuman antibody (e.g., mice genetically modified to produce humanantibodies) and screening clones that bind cadherin-11. See, e.g.,Lonberg and Huszar (1995) Human antibodies from transgenic mice, Int.Rev. Immunol. 13:65-93, which is incorporated herein by reference in itsentirety for methods of producing fully human antibodies. As usedherein, the term humanized and human in relation to antibodies, relateto any antibody which is expected to elicit a therapeutically tolerableweak immunogenic response in a human subject. Thus, the terms includefully humanized or fully human as well as partially humanized orpartially human. If reference is made herein to use of a humanizedantibody, a human antibody can be substituted or vice versa.

Humanized forms of non-human (e.g., murine) antibodies are chimericimmunoglobulins, immunoglobulin chains or fragments thereof (such as Fv,Fab, Fab′, F(ab′)2, or other antigen-binding subsequences of antibodies)which contain minimal sequence derived from non-human immunoglobulin.Humanized antibodies include human immunoglobulins (recipient antibody)in which residues from a complementary determining region (CDR) of therecipient are replaced by residues from a CDR of a non-human species(donor antibody) such as mouse, rat or rabbit having the desiredspecificity, affinity and capacity. In some instances, Fv frameworkresidues of the human immunoglobulin are replaced by correspondingnon-human residues. Humanized antibodies may also comprise residues thatare found neither in the recipient antibody nor in the imported CDR orframework sequences. In general, the humanized antibody will comprisesubstantially all or at least one, and typically two, variable domains,in which all or substantially all of the CDR regions correspond to thoseof a non-human immunoglobulin and all or substantially all of the FRregions are those of a human immunoglobulin consensus sequence. Thehumanized antibody optimally also will comprise at least a portion of animmunoglobulin constant region (Fc), typically that of a humanimmunoglobulin (Jones et al., Nature, 321:522-525 (1986); Riechmann etal., Nature, 332:323-327 (1988); and Presta, Curr. Op. Struct. Biol.,2:593-596 (1992)).

Generally, a humanized antibody has one or more amino acid residuesintroduced into it from a source that is non-human. These non-humanamino acid residues are often referred to as import residues, which aretypically taken from an import variable domain. Humanization can beessentially performed following the methods described in Jones et al.,Nature, 321:522-525 (1986); Riechmann et al., Nature, 332:323-327(1988); or Verhoeyen et al., Science, 239:1534-1536 (1988)), bysubstituting rodent CDRs or CDR sequences for the correspondingsequences of a human antibody. Accordingly, such humanized antibodiesare chimeric antibodies (U.S. Pat. No. 4,816,567), wherein substantiallyless than an intact human variable domain has been substituted by thecorresponding sequence from a non-human species. In practice, humanizedantibodies are typically human antibodies in which some CDR residues andpossibly some FR residues are substituted by residues from analogoussites in rodent antibodies.

The provided antibody or fragment can be labeled or fused with anotherpolypeptide or fragment thereof. For example, the provided antibodies orfragments thereof can be fused with a therapeutic agent. Thus, anantibody or fragment thereof that binds to cadherin-11 may be linked toa therapeutic agent. The linkage can be covalent or noncovalent (e.g.,ionic). Therapeutic agents include but are not limited to toxins,including but not limited to plant and bacterial toxins, smallmolecules, peptides, polypeptides and proteins. Genetically engineeredfusion proteins, in which genes encoding for an antibody or fragmentsthereof, including the Fv region, can be fused to the genes encoding atoxin to deliver a toxin to the target cell are also provided. As usedherein, a target cell or target cells are cadherin-11 positive cells,including for example, cancer cells. The antibodies taught herein canalso be directly or indirectly labeled and used, for example, indiagnostic methods to detect cadherin-11.

One or more of the compounds described herein or pharmaceuticallyacceptable salts or prodrugs thereof can be provided in a pharmaceuticalcomposition. Depending on the intended mode of administration, thepharmaceutical composition can be formulated in accordance with its use.The compositions will include a therapeutically effective amount of oneor more of the compounds described herein or derivatives thereof incombination with a pharmaceutically acceptable carrier and, in addition,can include other agents, including other therapeutic agents. Thesecompositions can be prepared in any manner available in the art, and canbe administered in a number of ways depending on whether local orsystemic treatment is desired, and on the area to be treated. Thus, thedisclosed compositions can be administered, for example, orally,parenterally (e.g., intravenously), intraventricularly, intramuscularly,intraperitoneally, transdermally, extracorporeally, or topically. Thecompositions can be administered locally (e.g., into a tumor).

By pharmaceutically acceptable is meant a material that is notbiologically or otherwise undesirable, which can be administered to anindividual along with the selected compound without causing unacceptablebiological effects or interacting in a deleterious manner with the othercomponents of the pharmaceutical composition in which it is contained.

As used herein, the term carrier encompasses any excipient, diluent,filler, salt, buffer, stabilizer, solubilizer, lipid, stabilizer, orother material well known in the art for use in pharmaceuticalformulations. The choice of a carrier for use in a composition willdepend upon the intended route of administration for the composition.The preparation of pharmaceutically acceptable carriers and formulationscontaining these materials is described in, e.g., Remington'sPharmaceutical Sciences, 21st Edition, ed. University of the Sciences inPhiladelphia, Lippincott, Williams & Wilkins, Philadelphia Pa., 2005.Examples of physiologically acceptable carriers include buffers such asphosphate buffers, citrate buffer, and buffers with other organic acids;antioxidants including ascorbic acid; low molecular weight (less thanabout 10 residues) polypeptides; proteins, such as serum albumin,gelatin, or immunoglobulins; hydrophilic polymers such aspolyvinylpyrrolidone; amino acids such as glycine, glutamine,asparagine, arginine or lysine; monosaccharides, disaccharides, andother carbohydrates including glucose, mannose, or dextrins; chelatingagents such as EDTA; sugar alcohols such as mannitol or sorbitol;salt-forming counterions such as sodium; and/or nonionic surfactantssuch as TWEEN® (ICI, Inc.; Bridgewater, N.J.), polyethylene glycol(PEG), and PLURONICS™ (BASF; Florham Park, N.J.).

Compositions containing the compound described herein orpharmaceutically acceptable salts or prodrugs thereof suitable forparenteral injection can comprise physiologically acceptable sterileaqueous or nonaqueous solutions, dispersions, suspensions or emulsions,and sterile powders for reconstitution into sterile injectable solutionsor dispersions. Examples of suitable aqueous and nonaqueous carriers,diluents, solvents or vehicles include water, ethanol, polyols(propyleneglycol, polyethyleneglycol, glycerol, and the like), suitablemixtures thereof, vegetable oils (such as olive oil) and injectableorganic esters such as ethyl oleate. Proper fluidity can be maintained,for example, by the use of a coating such as lecithin, by themaintenance of the required particle size in the case of dispersions andby the use of surfactants.

These compositions can also contain adjuvants such as preserving,wetting, emulsifying, and dispensing agents. Prevention of the action ofmicroorganisms can be promoted by various antibacterial and antifungalagents, for example, parabens, chlorobutanol, phenol, sorbic acid, andthe like. Isotonic agents, for example, sugars, sodium chloride, and thelike can also be included. Prolonged absorption of the injectablepharmaceutical form can be brought about by the use of agents delayingabsorption, for example, aluminum monostearate and gelatin.

Solid dosage forms for oral administration of the compounds describedherein or pharmaceutically acceptable salts or prodrugs thereof includecapsules, tablets, pills, powders, and granules. In such solid dosageforms, the compounds described herein or derivatives thereof is admixedwith at least one inert customary excipient (or carrier) such as sodiumcitrate or dicalcium phosphate or (a) fillers or extenders, as forexample, starches, lactose, sucrose, glucose, mannitol, and silicicacid, (b) binders, as for example, carboxymethylcellulose, alignates,gelatin, polyvinylpyrrolidone, sucrose, and acacia, (c) humectants, asfor example, glycerol, (d) disintegrating agents, as for example,agar-agar, calcium carbonate, potato or tapioca starch, alginic acid,certain complex silicates, and sodium carbonate, (e) solution retarders,as for example, paraffin, (f) absorption accelerators, as for example,quaternary ammonium compounds, (g) wetting agents, as for example, cetylalcohol, and glycerol monostearate, (h) adsorbents, as for example,kaolin and bentonite, and (i) lubricants, as for example, talc, calciumstearate, magnesium stearate, solid polyethylene glycols, sodium laurylsulfate, or mixtures thereof. In the case of capsules, tablets, andpills, the dosage forms can also comprise buffering agents.

Solid compositions of a similar type can also be employed as fillers insoft and hard-filled gelatin capsules using such excipients as lactoseor milk sugar as well as high molecular weight polyethyleneglycols, andthe like.

Solid dosage forms such as tablets, dragees, capsules, pills, andgranules can be prepared with coatings and shells, such as entericcoatings and others known in the art. They can contain opacifying agentsand can also be of such composition that they release the activecompound or compounds in a certain part of the intestinal tract in adelayed manner. Examples of embedding compositions that can be used arepolymeric substances and waxes. The active compounds can also be inmicro-encapsulated form, if appropriate, with one or more of theabove-mentioned excipients.

Liquid dosage forms for oral administration of the compounds describedherein or pharmaceutically acceptable salts or prodrugs thereof includepharmaceutically acceptable emulsions, solutions, suspensions, syrups,and elixirs. In addition to the active compounds, the liquid dosageforms can contain inert diluents commonly used in the art, such as wateror other solvents, solubilizing agents, and emulsifiers, as for example,ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzylalcohol, benzyl benzoate, propyleneglycol, 1,3-butyleneglycol,dimethylformamide, oils, in particular, cottonseed oil, groundnut oil,corn germ oil, olive oil, castor oil, sesame oil, glycerol,tetrahydrofurfuryl alcohol, polyethyleneglycols, and fatty acid estersof sorbitan, or mixtures of these substances, and the like.

Besides such inert diluents, the composition can also include additionalagents, such as wetting, emulsifying, suspending, sweetening, flavoring,or perfuming agents.

Suspensions, in addition to the active compounds, can contain additionalagents, as for example, ethoxylated isostearyl alcohols, polyoxyethylenesorbitol and sorbitan esters, microcrystalline cellulose, aluminummetahydroxide, bentonite, agar-agar and tragacanth, or mixtures of thesesubstances, and the like.

Compositions of the compounds described herein or pharmaceuticallyacceptable salts or prodrugs thereof for rectal administrations areoptionally suppositories, which can be prepared by mixing the compoundswith suitable non-irritating excipients or carriers such as cocoabutter, polyethyleneglycol or a suppository wax, which are solid atordinary temperatures but liquid at body temperature and therefore, meltin the rectum or vaginal cavity and release the active component.

Dosage forms for topical administration of the compounds describedherein or pharmaceutically acceptable salts or prodrugs thereof includeointments, powders, sprays, and inhalants. The compounds describedherein or pharmaceutically salts or prodrugs thereof are admixed understerile conditions with a physiologically acceptable carrier and anypreservatives, buffers, or propellants as can be required. Ophthalmicformulations, ointments, powders, and solutions are also contemplated asbeing within the scope of the compositions.

The term pharmaceutically acceptable salts as used herein refers tothose salts of the compound described herein or derivatives thereof thatare, within the scope of sound medical judgment, suitable for use incontact with the tissues of subjects without undue toxicity, irritation,allergic response, and the like, commensurate with a reasonablebenefit/risk ratio, and effective for their intended use, as well as thezwitterionic forms, where possible, of the compounds described herein.The term salts refers to the relatively non-toxic, inorganic and organicacid addition salts of the compounds described herein. These salts canbe prepared in situ during the isolation and purification of thecompounds or by separately reacting the purified compound in its freebase form with a suitable organic or inorganic acid and isolating thesalt thus formed. Representative salts include the hydrobromide,hydrochloride, sulfate, bisulfate, nitrate, acetate, oxalate, valerate,oleate, palmitate, stearate, laurate, borate, benzoate, lactate,phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate,naphthylate mesylate, glucoheptonate, lactobionate, methane sulphonate,and laurylsulphonate salts, and the like. These can include cationsbased on the alkali and alkaline earth metals, such as sodium, lithium,potassium, calcium, magnesium, and the like, as well as non-toxicammonium, quaternary ammonium, and amine cations including, but notlimited to ammonium, tetramethylammonium, tetraethylammonium,methylamine, dimethylamine, trimethylamine, triethylamine, ethylamine,and the like. (See Stahl and Wermuth, Pharmaceutical Salts: Properties,Selection, and Use, Wiley-VCH, 2008, which is incorporated herein byreference in its entirety, at least, for compositions taught herein.)

The compounds and derivatives thereof described herein are useful intreating cadherin-11 related diseases and conditions in humans (e.g.,including pediatric and geriatric populations) and animals (e.g.,veterinary applications). The methods described herein compriseadministering to a subject a therapeutically effective amount of thecompounds described herein or a pharmaceutically acceptable salt orprodrug thereof. Examples of cadherin-11 related diseases includerheumatoid arthritis and cancer (e.g., breast cancer, prostate cancer,glioma, glioblastoma, myeloma, leukemia, osteosarcomas, oral squamouscell cancer, renal cell cancer, colon cancer, and gastric cancer).

The methods and compounds as described herein are useful for bothprophylactic and therapeutic treatment. For prophylactic use, atherapeutically effective amount of the compounds described herein orderivatives thereof are administered to a subject prior to onset (e.g.,before obvious signs of a cadherin-11 related disease), during earlyonset (e.g., upon initial signs and symptoms of a cadherin-11 relateddisease), or during an established cadherin-11 related disease.Prophylactic administration can occur for several days to years prior tothe manifestation of symptoms of the cadherin-11 related disease.Prophylactic administration can be used, for example, in thepreventative treatment of subjects diagnosed with a genetic cadherin-11related disease. Therapeutic treatment involves administering to asubject a therapeutically effective amount of the compounds describedherein or derivatives thereof after a cadherin-11 related disease isdiagnosed.

Administration of compounds described herein or pharmaceuticallyacceptable salts or prodrugs thereof can be carried out usingtherapeutically effective amounts of the compounds described herein orpharmaceutically acceptable salts or prodrugs thereof for periods oftime effective to treat the cadherin-11 related disease or disorder. Theeffective amount of the compounds described herein or pharmaceuticallyacceptable salts or prodrugs thereof can be determined by one ofordinary skill in the art and includes exemplary dosage amounts for amammal of from about 0.5 to about 200 mg/kg of body weight of activecompound per day, which can be administered in a single dose or in theform of individual divided doses, such as from 1 to 4 times per day.Alternatively, the dosage amount can be from about 0.5 to about 150mg/kg of body weight of active compound per day, about 0.5 to 100 mg/kgof body weight of active compound per day, about 0.5 to about 75 mg/kgof body weight of active compound per day, about 0.5 to about 50 mg/kgof body weight of active compound per day, about 0.5 to about 25 mg/kgof body weight of active compound per day, about 1 to about 20 mg/kg ofbody weight of active compound per day, about 1 to about 10 mg/kg ofbody weight of active compound per day, about 20 mg/kg of body weight ofactive compound per day, about 10 mg/kg of body weight of activecompound per day, or about 5 mg/kg of body weight of active compound perday. Those of skill in the art will understand that the specific doselevel and frequency of dosage for any particular subject will vary andwill depend upon a variety of factors, including the activity of thespecific compound employed, the metabolic stability and length of actionof that compound, the species, age, body weight, general health, sex anddiet of the subject, the mode and time of administration, rate ofexcretion, drug combination, and severity of the particular condition.

The method of treating or preventing a cadherin-11 related disease in asubject can further comprise administering to the subject a therapeuticagent or radiation therapy or a combination thereof. Thus, the providedcompositions and methods can include one or more additional agents. Theone or more additional agents and the compounds described herein orpharmaceutically acceptable salts or prodrugs thereof can beadministered in any order, including simultaneous administration, aswell as temporally spaced order of up to several days apart. The methodscan also include more than a single administration of the one or moreadditional agents and/or the compounds described herein orpharmaceutically acceptable salts or prodrugs thereof. Theadministration of the one or more additional agents and the compoundsdescribed herein or pharmaceutically acceptable salts or prodrugsthereof can be by the same or different routes and concurrently orsequentially.

Therapeutic agents include but are not limited to chemotherapeuticagents, antibodies, antivirals, steroidal and non-steroidalanti-inflammatories, conventional immunotherapeutic agents, cytokines,chemokines, and/or growth factors.

The therapeutic agent can, for example, be a chemotherapeutic agent. Achemotherapeutic agent is a compound or composition effective ininhibiting or arresting the growth of an abnormally growing cell. Thus,such an agent may be used therapeutically to treat cancer as well asother diseases marked by abnormal cell growth. Illustrative examples ofanti-cancer compounds include, but are not limited to, bexarotene,gefitinib, erlotinib, gemcitabine, paclitaxel, docetaxel, topotecan,irinotecan, vinorelbine, capecitabine, leucovorin, oxaliplatin,bevacizumab, cetuximab, panitumumab, bortezomib, oblimersen,hexamethylmelamine, ifosfamide, CPT-11, deflunomide, cycloheximide,dicarbazine, asparaginase, mitotant, vinblastine sulfate, carboplatin,colchicine, etoposide, melphalan, 6-mercaptopurine, teniposide,vinblastine, antibiotic derivatives (e.g. anthracyclines such asdoxorubicin, liposomal doxorubicin, and diethylstilbestrol doxorubicin,bleomycin, daunorubicin, and dactinomycin); antiestrogens (e.g.,tamoxifen); antimetabolites (e.g., fluorouracil (FU), 5-FU,methotrexate, floxuridine, interferon alpha-2B, glutamic acid,plicamycin, mercaptopurine, and 6-thioguanine); cytotoxic agents (e.g.,carmustine, BCNU, lomustine, CCNU, cytosine arabinoside,cyclophosphamide, estramustine, hydroxyurea, procarbazine, mitomycin,busulfan, cisplatin, vincristine and vincristine sulfate); hormones(e.g., medroxyprogesterone, estramustine phosphate sodium, ethinylestradiol, estradiol, megestrol acetate, methyltestosterone,diethylstilbestrol diphosphate, chlorotrianisene, and testolactone);nitrogen mustard derivatives (e.g., mephalen, chlorambucil,mechlorethamine (nitrogen mustard) and thiotepa); and steroids (e.g.,bethamethasone sodium phosphate). Optionally, the chemotherapeutic agentis temozolomide, or carmustine.

Any of the aforementioned therapeutic agents can be used in anycombination with the compositions described herein. Combinations areadministered either concomitantly (e.g., as an admixture), separatelybut simultaneously (e.g., via separate intravenous lines into the samesubject), or sequentially (e.g., one of the compounds or agents is givenfirst followed by the second). Thus, the term combination is used torefer to concomitant, simultaneous, or sequential administration of twoor more agents.

Also provided herein are kits for preventing or treating a cadherin-11disease in a subject. A kit can include any of the compounds orcompositions described herein. For example, a kit can include a compoundof Formula I, Formula II, the additional cadherin-11 inhibitorsdescribed herein, or combinations thereof. A kit can further include oneor more anti-inflammatory agents. A kit can also include one or morechemotherapeutic agents. A kit can include an oral formulation of any ofthe compounds or compositions described herein. A kit can additionallyinclude directions for use of the kit (e.g., instructions for treating asubject). A kit can include a means of administering the compound orcomposition or a vessel for containing the compound or composition.

Provided herein is a method for determining whether a subject has or isat risk for developing cancer. The method includes the steps ofobtaining a biological sample from the subject and determining the levelof expression of cadherin-11 in the sample, wherein an increase inexpression as compared to a control indicates the subject has or is atrisk for developing cancer. Optionally, the cancer is renal cell cancer,prostate cancer, breast cancer, glioma, glioblastoma, myeloma, orleukemia. Optionally, the cancer exhibits morphologic and molecularchanges characteristic of mesenchymal tissue (i.e., mesenchymal-likecancer) or has a basal-like phenotype (i.e., a basal-like cancer).Optionally, the cancer is metastatic or has a poor prognosis or isinvasive.

An increased or higher level in expression or activity of cadherin-11 ascompared to a control means that the level of expression or activity ofcadherin-11 is higher in the biological sample from a subject beingtested than in a control sample. As used throughout, higher or increaseas compared to a control refer to increases above a control. As usedherein, control refers to a reference standard from, for example, anuntreated sample or subject, from a subject without cancer, an untreatedsubject with cancer. By way of another example, a control level can bethe level of expression or activity in a control sample in the absenceof a stimulus. Alternatively, a control level can be the level ofexpression or activity in a control sample from a subject or group ofsubjects without cancer. An increased or high level is optionallystatistically higher than a selected control using at least oneacceptable statistical analysis method.

As used herein a biological sample which is subjected to testing is asample derived from a subject and includes, but is not limited to, anycell, tissue or biological fluid. The sample can be, but is not limitedto, peripheral blood, plasma, urine, saliva, gastric secretion, feces,bone marrow specimens, primary or metastatic tumor biopsy, embeddedtissue sections, frozen tissue sections, cell preparations, cytologicalpreparations, exfoliate samples (e.g., sputum), fine needle aspirations,amnion cells, fresh tissue, dry tissue, and cultured cells or tissue.The biological sample can also be whole cells or cell organelles (e.g.,nuclei). A biological sample can also include a partially purifiedsample, cell culture, or a cell line.

Assay techniques that can be used to determine levels of expression in asample are well-known to those of skill in the art. Such assay methodsinclude radioimmunoassays, reverse transcriptase PCR (RT-PCR) assays,immunohistochemistry assays, in situ hybridization assays,competitive-binding assays, Western blot analyses, ELISA assays andproteomic approaches, two-dimensional gel electrophoresis (2Delectrophoresis) and non-gel based approaches such as mass spectrometryor protein interaction profiling. Assays also include, but are notlimited to, competitive and non-competitive assay systems usingtechniques such as radioimmunoassays, enzyme immunoassays (EIA), enzymelinked immunosorbent assay (ELISA), sandwich immunoassays, precipitinreactions, gel diffusion reactions, immunodiffusion assays,agglutination assays, complement-fixation assays, immunoradiometricassays, fluorescent immunoassays, protein A immunoassays, andimmunoelectrophoresis assays. For examples of immunoassay methods, seeU.S. Pat. Nos. 4,845,026 and 5,006,459.

For diagnostic methods, an antigen binding partner, for example, anantibody, can be labeled with a detectable moiety and used to detect theantigen in a sample. The antibody can be directly labeled or indirectlylabeled (e.g., by a secondary or tertiary antibody that is labeled witha detectable moiety). Numerous labels are available including, but notlimited to radioisotopes, fluorescent labels, and enzyme-substratelabels. Radioisotopes include, for example, ³⁵S, ¹⁴C, ¹²⁵I, ³H, and ¹³¹IFluorescent labels include, for example, rare earth chelates (europiumchelates), fluorescein and its derivatives, rhodamine and itsderivatives, dansyl, Lissamine, phycoerythrin and Texas Red. The labelscan be conjugated to the antigen binding partner using the techniquesdisclosed in Current Protocols in Immunology, Volumes 1 and 2, Coligenet al., Ed., Wiley-Interscience, New York, N.Y., Pubs., (1991), forexample.

When using enzyme-substrate labels, the enzyme preferably catalyses achemical alteration of the chromogenic substrate which can be measuredusing various techniques. For example, the enzyme may catalyze a colorchange in a substrate, which can be measured spectrophotometrically.Alternatively, the enzyme may alter the fluorescence orchemiluminescence of the substrate. The chemiluminescent substratebecomes electronically excited by a chemical reaction and may then emitlight which can be measured (using a chemiluminometer, for example) ordonates energy to a fluorescent acceptor. Examples of enzymatic labelsinclude luciferases (e.g., firefly luciferase and bacterial luciferase),luciferin, 2,3-dihydrophthalazinediones, malate dehydrogenase, urease,peroxidase such as horseradish peroxidase (HRPO), alkaline phosphatase,Θ-galactosidase, glucoamylase, lysozyme, saccharide oxidases (e.g.,glucose oxidase, galactose oxidase, and glucose-6-phosphatedehydrogenase), heterocyclic oxidases (such as uricase and xanthineoxidase), lactoperoxidase, microperoxidase, and the like. Techniques forconjugating enzymes are described in O'Sullivan et al., Methods for thePreparation of Enzyme-Antibody Conjugates for use in Enzyme Immunoassay,in Methods in Enzym. (ed J. Langone & H. Van Vunakis), Academic press,New York, 73: 147-166 (1981). Examples of enzyme-substrate combinationsinclude, for example, horseradish peroxidase (HRPO) with hydrogenperoxidase as a substrate, alkaline phosphatase (AP) withpara-Nitrophenyl phosphate as chromogenic substrate, andΘ-D-galactosidase (Θ-D-Gal) with a chromogenic substrate (e.g.p-nitrophenyl-Θ-D-galactosidase) or fluorogenic substrate4-methylumbelliferyl-Θ-D-galactosidase.

In an ELISA assay, an antibody is prepared, if not readily availablefrom a commercial source, specific to an antigen. In addition, areporter antibody generally is prepared which binds specifically to theantigen. The reporter antibody is attached to a detectable reagent suchas a radioactive, fluorescent or enzymatic reagent, for examplehorseradish peroxidase enzyme or alkaline phosphatase. To carry out theELISA, antibody specific to antigen is incubated on a solid support,e.g., a polystyrene dish, that binds the antibody. Any free proteinbinding sites on the dish are then covered by incubating with anon-specific protein such as bovine serum albumin. Next, the sample tobe analyzed is incubated in the dish, during which time the antigenbinds to the specific antibody attached to the polystyrene dish. Unboundsample is washed out with buffer. A reporter antibody specificallydirected to the antigen and linked to a detectable reagent such ashorseradish peroxidase is placed in the dish resulting in binding of thereporter antibody to any antibody bound to the antigen. Unattachedreporter antibody is then washed out. Reagents for peroxidase activity,including a colorimetric substrate are then added to the dish.Immobilized peroxidase, linked to antibodies, produces a coloredreaction product. The amount of color developed in a given time periodis proportional to the amount of antigen present in the sample.Quantitative results typically are obtained by reference to a standardcurve.

A competition assay can also be employed wherein antibodies specific toantigen are attached to a solid support and labeled antigen and a samplederived from the subject or control are passed over the solid support.The amount of label detected which is attached to the solid support canbe correlated to a quantity of antigen in the sample.

Of the proteomic approaches, 2D electrophoresis is a technique wellknown to those in the art. Isolation of individual proteins from asample such as serum is accomplished using sequential separation ofproteins by different characteristics usually on polyacrylamide gels.First, proteins are separated by size using an electric current. Thecurrent acts uniformly on all proteins, so smaller proteins move fartheron the gel than larger proteins. The second dimension applies a currentperpendicular to the first and separates proteins not on the basis ofsize but on the specific electric charge carried by each protein. Sinceno two proteins with different sequences are identical on the basis ofboth size and charge, the result of a 2D separation is a square gel inwhich each protein occupies a unique spot. Analysis of the spots withchemical or antibody probes, or subsequent protein microsequencing canreveal the relative abundance of a given protein and the identity of theproteins in the sample.

Optionally, a genetic sample from the biological sample can be obtained.The genetic sample comprises a nucleic acid, preferably RNA and/or DNA.For example, in determining the expression of genes mRNA can be obtainedfrom the biological sample, and the mRNA may be reverse transcribed intocDNA for further analysis. Alternatively, the mRNA itself is used indetermining the expression of genes.

A genetic sample may be obtained from the biological sample using anytechniques known in the art (Ausubel et al. Current Protocols inMolecular Biology (John Wiley & Sons, Inc., New York, 1999); MolecularCloning: A Laboratory Manual, 2nd Ed., ed. by Sambrook, Fritsch, andManiatis (Cold Spring Harbor Laboratory Press: 1989); Nucleic AcidHybridization (B. D. Hames & S. J. Higgins eds. 1984)). The nucleic acidmay be purified from whole cells using DNA or RNA purificationtechniques. The genetic sample may also be amplified using PCR or invivo techniques requiring subcloning. The genetic sample can be obtainedby isolating mRNA from the cells of the biological sample and reversetranscribing the RNA into DNA in order to create cDNA (Khan et al.Biochem. Biophys. Acta 1423:17 28, 1999).

Once a genetic sample has been obtained, it can be analyzed for thepresence or absence of one or more particular genes encoding, forexample, cadherin-11. The analysis may be performed using any techniquesknown in the art including, but not limited to, sequencing, PCR, RT-PCR,quantitative PCR, restriction fragment length polymorphism,hybridization techniques, Northern blot, microarray technology, DNAmicroarray technology, and the like. In determining the expression levelof a gene or genes in a genetic sample, the level of expression may benormalized by comparison to the expression of another gene such as awell known, well characterized gene or a housekeeping gene. For example,reverse-transcriptase PCR (RT-PCR) can be used to detect the presence ofa specific mRNA population in a complex mixture of thousands of othermRNA species. In RT-PCR, an mRNA species is first reverse transcribed tocomplementary DNA (cDNA) with use of the enzyme reverse transcriptase;the cDNA is then amplified as in a standard PCR reaction. RT-PCR canthus reveal by amplification the presence of a single species of mRNA.

Hybridization to clones or oligonucleotides arrayed on a solid support(i.e., gridding) can be used to both detect the expression of andquantitate the level of expression of that gene. In this approach, acDNA encoding an antigen is fixed to a substrate. The substrate may beof any suitable type including but not limited to glass, nitrocellulose,nylon, or plastic. At least a portion of the DNA encoding the antigen isattached to the substrate and then incubated with the analyte, which maybe RNA or a complementary DNA (cDNA) copy of the RNA, isolated from thesample of interest. Hybridization between the substrate bound DNA andthe analyte can be detected and quantitated by several means includingbut not limited to radioactive labeling or fluorescence labeling of theanalyte or a secondary molecule designed to detect the hybrid.Quantitation of the level of gene expression can be done by comparisonof the intensity of the signal from the analyte compared with thatdetermined from known standards. The standards can be obtained by invitro transcription of the target gene, quantitating the yield, and thenusing that material to generate a standard curve.

As used throughout, subject can be a vertebrate, more specifically amammal (e.g., a human, horse, cat, dog, cow, pig, sheep, goat, mouse,rabbit, rat, and guinea pig), birds, reptiles, amphibians, fish, and anyother animal. The term does not denote a particular age or sex. Thus,adult and newborn subjects, whether male or female, are intended to becovered. As used herein, patient or subject may be used interchangeablyand can refer to a subject with a disease or disorder (e.g., cancer).The term patient or subject includes human and veterinary subjects.

As used herein the terms treatment, treat, or treating refers to amethod of reducing the effects of a disease or condition or symptom ofthe disease or condition. Thus in the disclosed method, treatment canrefer to a 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100%reduction in the severity of an established disease or condition or oneor more symptoms of the disease or condition. For example, a method fortreating a disease is considered to be a treatment if there is a 10%reduction in one or more symptoms or signs (e.g., size of the tumor orrate of tumor growth) of the disease in a subject as compared to acontrol. Thus the reduction can be a 10%, 20%, 30%, 40%, 50%, 60%, 70%,80%, 90%, 100%, or any percent reduction in between 10% and 100% ascompared to native or control levels. It is understood that treatmentdoes not necessarily refer to a cure or complete ablation of thedisease, condition, or symptoms of the disease or condition.

As used herein, the terms prevent, preventing, and prevention of adisease or disorder refers to an action, for example, administration ofa composition or therapeutic agent, that occurs before or at about thesame time a subject begins to show one or more symptoms of the diseaseor disorder, which inhibits or delays onset or severity of one or moresymptoms of the disease or disorder. As used herein, references todecreasing, reducing, or inhibiting include a change of 10%, 20%, 30%,40%, 50%, 60%, 70%, 80%, 90% or greater as compared to a control level.Such terms can include but do not necessarily include completeelimination.

Disclosed are materials, compositions, and components that can be usedfor, can be used in conjunction with, can be used in preparation for, orare products of the disclosed methods and compositions. These and othermaterials are disclosed herein, and it is understood that whencombinations, subsets, interactions, groups, etc. of these materials aredisclosed that while specific reference of each various individual andcollective combinations and permutations of these compounds may not beexplicitly disclosed, each is specifically contemplated and describedherein. For example, if a method is disclosed and discussed and a numberof modifications that can be made to a number of molecules including themethod are discussed, each and every combination and permutation of themethod, and the modifications that are possible are specificallycontemplated unless specifically indicated to the contrary. Likewise,any subset or combination of these is also specifically contemplated anddisclosed. This concept applies to all aspects of this disclosureincluding, but not limited to, steps in methods using the disclosedcompositions. Thus, if there are a variety of additional steps that canbe performed, it is understood that each of these additional steps canbe performed with any specific method steps or combination of methodsteps of the disclosed methods, and that each such combination or subsetof combinations is specifically contemplated and should be considereddisclosed.

Throughout this application, various publications are referenced. Thedisclosures of these publications in their entireties are herebyincorporated by reference into this application.

A number of aspects have been described. Nevertheless, it will beunderstood that various modifications may be made. Furthermore, when onecharacteristic or step is described it can be combined with any othercharacteristic or step herein even if the combination is not explicitlystated. Accordingly, other aspects are within the scope of the claims.

The examples below are intended to further illustrate certain aspects ofthe methods and compounds described herein, and are not intended tolimit the scope of the claims.

EXAMPLES Example 1 Cell Culture and Generation of Stable Cell Lines

To investigate the specific role of cadherin-11 in breast cancer, RNAinterference to knockdown endogenous cadherin-11 expression inaggressive breast and prostate cancer cells was employed. Specifically,MDA-MB-231 breast cancer cells were used for stable transfection ofsiRNA or infection of shRNA, along with PC-3 prostate cancer cells,targeting the wild type isoform of cadherin-11 via its intracellulardomain. The siRNA target sequence was designed using a database, placedinto a commercial vector, and further transfected into MDA-MB-231 cells.Transient expression of the siRNA was determined by examination ofcadherin-11 protein for ample knockdown. Upon confirmation, the siRNAvector was cotransfected with a second vector, one allowing for stableselection of RNAi-containing cells, and MDA-MB-231 breast cancer cells.Selected clones were pooled, and the entire process was repeated intriplicate to obtain more homogenous pools of stable cells (FIG. 2). Inaddition, lentiviral particles containing two separate shRNA sequencestargeting the same region of cadherin-11 were used to infect MDA-MB-231cells, as well as PC-3 prostate cancer cells for validation in alternatecancers. Upon stable selection, single-cell cloning was employed toobtain a more pure population of testable cells. Cadherin-11 expressionwas determined in the resulting stable cell lines at both the RNA levelby quantitative RT-PCR and protein by Western blot. Consequently, stablecells for all experiments discussed were chosen based upon immunoblotexpression (see Example 2 for experimental details). Two cell lines,chosen from among the pooled siRNA-targeted stables tested, along withone clonal cell line from each of the two shRNA sequence-targetedstables created (54333 and 54334), were selected for use in theseexperiments based upon their favorable level of knockdown. Specifically,parental breast cancer lines (MDA-MB-231) and prostate cancer cell lines(PC-3) (American Type Culture Collection; Manassas, Va.) were maintainedin Dulbecco's Modified Eagle Medium (DMEM, Invitrogen, Carlsbad, Calif.)supplemented with 5% fetal bovine serum. siRNA pooled stables werecreated using siRNA templates containing T7 promoter sequences at the 3′end of the sequence and an AA 5′ overhang (Integrated DNA Technologies,Inc.; Coralville, Iowa), using anti-sense sequence5′-AACAGCGTGGATGTCGATGACCCTG TCTC-3′ (SEQ ID NO:1) and sense sequence5′-AAGTCATCGACATCCACGCT GCCTGTCTC-3′ (SEQ ID NO:2) to target cadherin-11wt isoform. Double-stranded siRNA vectors were synthesized using theSilencer™ siRNA Construction Kit (Ambion; Foster City, Calif.) andco-transfected with hygromycin B-resistant vector or vector alone intoMDA-MB-231 using Fugene (Roche Diagnostics; Indianapolis, Ind.). Stablecell clones were selected using lmg/mL Hygromycin B and maintained using0.5 mg/mL of antibiotic. The entire transfection process was repeatedthree times consecutively, with stable cell clones being selected ineach instance. Following final selection, five clones were selected atrandom and pooled to create stable cell lines for further analysis.shRNA Lentiviral stable cells were created using MISSION® shRNAlentiviral transduction particles (Sigma-Aldrich; St. Louis, Mo.)directed against human cadherin-11/OB-cadherin. Single cell clones wereselected in 15 μg/mL puromycin and maintained for further analysis in 10μg/mL antibiotic. All stable cell lines used in further studies wereselected from those generated based upon cadherin-11 protein expressionas measured by Western blot analysis.

Example 2 Immunoblot Assay

Confluent cells from 6-cm tissue culture dishes were isolated viascraping in RIPA lysis buffer solution consisting of RIPA, NaF, NaV, anda protease inhibitor on ice. The lysates were homogenized using a25-gauge needle, rotated for 15 min at 4° C., and then centrifuged at15,000 rpm for 15 min to remove insoluble material. The protein in thesupernatant was quantified using a Bio-Rad DC protein assay according tosupplied protocol. The protein samples were prepared in 1×LDS samplebuffer and 1×DTT reducing agent and then boiled for 10 min. 30 μgprotein was separated on a 3-8% Tris-Acetate NuPage gel (Novex;Carlsbad, Calif.), transferred to nitrocellulose (Millipore; Billerica,Mass.), and blocked for 1 h at room temperature in PBS-Tweensupplemented with 5% milk. The blots were probed with monoclonalantibodies recognizing cadherin-11 wt (5B2H5: Zymed) and GAPDH as aloading control. A secondary peroxidase-labelled antibody (Kirkegaardand Perry Laboratories, Inc.; Gaithersburg, Md.) was used on the blots,and the resulting bands were visualized using ECL (Amersham; Amersham,UK).

Example 3 Computational Methods of Screening Small Molecule Cadherin-11Inhibitors

Small molecule inhibitors were tested for potential use in targetedcancer therapies. A computer-based model of structural modeling was usedto predict small molecules capable of binding to specific hydrophobicpockets in the cadherin-11 extracellular domain, EC1. Unlike othercadherins, cadherin-11 is found at regions of cell-extracellular matrixcontact in addition to cell-cell contact sites. Consistent with this,cadherin-11 possesses a site in EC1 similar to the matrix-interactingsite of integrins, and the cadherin-11 splice variant is sequestered inthe extracellular matrix. The crystal structure of cadherin-11 wasrecently solved and confirmed that the region targeted by the firstgeneration blockers is not involved in cell-cell interactions andrevealed two other potential sites for interference of cell-celladhesion. This structure was used as a basis for docking molecularsimulations and the production of pharmacophores designed to block oneor both of the two adjacent regions (P1 and P2), which are necessary forcadherin-11 function in cell-cell adhesion.

Tryptophan binding pockets of the first extracellular (EC1) domain ofcadherin-11 (type 2) and N-cadherin (type 1) were compared and aflexible in-silico screening approach was utilized to includeflexibility in the EC1 structure homo- and hetero dimer interface.Ensembles of structures and molecular dynamics (MD) snapshots weregenerated. Their subsets of representative conformations were used fordocking simulations to explore the conformational flexibility of theprotein and the induced-fit effect of the protein-ligand interactions toa greater extent. The “best fit” compounds were selected based on thescoring functions followed by our optimal reference binding mode (ORBM)approach and functionally tested in subsequent assays.

Example 4 Immunofluorescence

Cadherin-11 localization in the cell was also observed for each cellline using immunofluorescence. Cells were grown on 18-mm coverslips,fixed and permeabilized using cold methanol at −20° C. for 15 min, andblocked in 6% goat serum for 1 h at room temperature. Coverslips wereincubated with primary antibody (5B2H5: cadherin-11 monoconal antibody,and SHB7: beta-catenin polyclonal antibody) overnight at 4° C.Coverslips were washed and incubated with Fluorescein (Kirkegaard andPerry Laboratories, Inc.; Gaithersburg, Md.) or Texas Red-conjugated(Jackson ImmunoResearch Laboratories, Inc.; West Grove, Pa.) secondaryantibody for 1 h at room temperature. Coverslips were washed and mountedusing Vectashield fluorescence mounting medium and visualized with aNikon 6000 fluorescent microscope.

Cadherin-11 is a transmembrane glycoprotein that works through theformation of adherens junctions, and thus logically resides at the cellmembrane. It was found that cadherin-11 expression was significantlyreduced in the cell lines containing RNAi with cadherin-11 targetedsequences, as compared to those possessing RNAi with a scrambledsequence or empty vector. Furthermore, cadherin-11 was localized at thecell membrane in the stable lines albeit minimally in RNAi-targetedcells. Also examined were p120 and beta-catenin levels in the stablecell lines. Beta-catenin expression remained relatively constant amongall cell lines, and its location was retained at the cell membrane.Morphology of the stable cell lines closely mimicked that of parentalMDA-MB-231 cells.

Example 5 Proliferation Assays

Cell adhesion affects cellular proliferation throughout development andin tumorigenesis. The exogenous expression of cadherin-11 in SKBR3breast cancer cells resulted in only a mild, non-significant increase inproliferation. However, knockdown of endogenous cadherin-11 in smoothmuscle cells significantly inhibited their proliferation. It wasinvestigated how the reduction of cadherin-11 in MDA-MB-231 breastcancer and PC-3 prostate cancer cells would affect their proliferativeability.

For crystal violet assays, cells were plated in triplicate in 96-welltissue culture dishes at 4 separate densities. Cells were grown in DMEMsupplemented with 5% fetal bovine serum for a period of 5 days. Dishesrepresenting growth were stained with crystal violet on Days 1, 3 and 5after plating, by removing growth medium, staining with 50 μL of crystalviolet stain for 10 min, then gently washing in dH₂O and allowing to dryovernight. Stained cells were solubilized in 100 μL 50/50 (v/v) 0.1Msodium citrate and ethanol for 15 min, and absorbance was read at 630λ.

For luminescence, the cells were plated in triplicate in 24-wellwhite-walled tissue culture dishes (Wallac; Waltham, Mass.) and grown inDMEM supplemented with 5% fetal bovine serum for 5 days. On the fifthday, the cells were resuspended in an equal volume of Cell-Titer-GloLuminescence Reagent (Promega; Madison, Wis.), which measures ATP, andincubated for 20 min at room temperature. The assay was measured usingluminescence.

Cadherin-11 knockdown yielded significant decreases in the ability ofthe cells to proliferate on plastic, as measured by crystal violet and afluorescent growth reagent. The assays were statistically repeatable andshow that cadherin-11 may play a role in breast cancer growth.

Example 6 Soft Agar Assays

To further characterize proliferative ability of cancer cells lackingcadherin-11, anchorage independent growth was studied in the stable celllines. 6-well tissue culture dishes were coated with 1.2 mL 0.6%Bacto-agar (Difco; Franklin Lakes, N.J.) in DMEM supplemented with 5%fetal bovine serum. Once set, the cells were plated in triplicate in0.3% agar (15,000/1 mL in each well) and layered gently on top of thecoated agar. The plates were incubated for 10 days to 2 weeks prior toreading using a colony counter (Omnicon; Manassas, Va.) and visualizedusing a SMZ-1500 stereoscope (Nikon; Tokyo, JP).

For luminescence, the cells were plated in triplicate in 24-wellwhite-walled tissue culture dishes (Wallac; Waltham, Mass.) as describedabove. On the final day, cells were resuspended in an equal volume ofCell-Titer-Glo Luminescence Reagent (Promega; Madison, Wis.), whichmeasures ATP, and incubated for 20 min at room temperature. The assaywas measured using luminescence.

Colony growth was observed and quantitated using a colony counter andconfirmed using a fluorescent growth reagent. Correspondingly, growthdifferences in soft agar exist among MDA-MB-231 cells and PC-3 uponstable reduction of cadherin-11. Breast cancer cells expressing littleto no cadherin-11 exhibited diminished colony formation in soft agar,which indicated an overall decrease in tumorigenic capability of thebreast cancer cells. The assays were repeatable in PC-3 prostate cancercells, which demonstrates the dominance of cadherin-11 among alternatecadherins expressed in these cells. Collectively, the growth studies inaggressive breast cancer cells show that adhesion molecule cadherin-11is required for malignant growth of MDA-MB-231 cells.

Example 7 Wound Healing Assays and Time-lapse Imaging

Throughout development, various cadherins are expressed to direct cellspecific differentiation. Cadherin expression in a given tissue dictatesits fate, a phenomenon dually observed in cancer. Cadherins specificallyregulate migration of developing cells, and knocking down cadherin-11 inmature smooth muscle cells or cranial neural crest cells inhibits theirmigratory ability. It is thought that malignant cells enhance or repressexpression of certain cadherins as to promote tumorigenicity as well asmetastatic potential of the tumor, for which invasive ability isessential. Upon addition of exogenous cadherin-11, non-metastatic SKBR3breast cancer cells demonstrated a significant increase in migratorypotential and invasion. To further characterize the stable cell lines,wound healing assays were performed to observe migration propensity ofMDA-MB-231 breast cancer cells and PC-3 prostate cancer cells withdepleted cadherin-11 expression.

The cells were plated in triplicate in 24-well tissue culture dishes andgrown to confluency in DMEM supplemented with 5% fetal bovine serum. Thecells were washed with 1×PBS, vertical wounds were made in each wellusing a 10 μL pipette tip, then growth medium was replaced. Images wererecorded using an Eclipse TE-300 inverted microscope (Nikon; Tokyo, JP)equipped with motorized stage, heated and CO₂— regulated incubator.Phase contrast images were taken every 1 h overnight. The migrationdistances were calculated by manually scaling of the wound width.

Reduction of cadherin-11 in highly metastatic MDA-MB-231 breast cancerand PC-3 prostate cancer cells produced significant decreases in theirmigration activity. Stable knockdown cells containing some detectablecadherin-11, albeit marginal (pooled RNAi 4A), displayed bettermigratory ability than those with minimal to no traceable expression,further implicating cadherin-11 responsibility for the observedphenotype. Altogether, these data show that cadherin-11 aids cancercells' ability to migrate.

Example 8 Matrigel Outgrowth Assays

Upon finding significant differences in growth and migration in cancercells with reduced cadherin-11 expression, invasive capability of thestable cell lines was explored in a 3-dimensional matrix. The cells wereplated in duplicate in a 12-well glass-bottom dish (MatTek; Ashland,Mass.) coated with 150 μL of Matrigel (BD Biosciences; San Jose,Calif.). The cells (5,000 cells/100 μl medium) were gently plated on topof the Matrigel layer directly and incubated 30 min at 37° C. Growthmedium (1 mL) was gently added to each well, and growth was visualizedusing a 5× objective on an AH2 Vanox inverted microscope (Olympus;Tokyo, JP) equipped with a CCD camera.

MDA-MB-231 breast cancer cells form branched networks when cultured on aMatrigel basement membrane-like matrix. It was observed that controlstable cells, either empty vector or scrambled target sequence, grew ina branched pattern through Matrigel mimicking their parental cell line.Stable cells with decreased cadherin-11 expression also spread in apattern similar to control and parental cell lines, however their rateof growth was greatly delayed. Control cells form branched networksapproximately 50% faster than their knockdown counterparts. These datashow that while cadherin-11 is not necessary for invasion of MDA-MB-231breast cancer cells, it is necessary for proper malignant growth.

Example 9 Animal Studies

MDA-MB-231 cells are an aggressive line and readily form tumors in nudemice. After observing significant growth differences among stable celllines in various assays in vitro, the translational continuity of theseobservations in xenografts was investigated. To that end, the stablecells were subcutaneously injected into athymic nude mice at fourventral sites such that each mouse contained at least one control cellline and two knockdowns in each representative position. Tumor growthwas assessed twice weekly with calipers for a minimum period of 6 weeks.The pooled stable cells containing the siRNA target sequence againstcadherin-11 failed to form tumors completely in nude mice, whereas theempty vector controls formed subcutaneous tumors as expected. Thisresult was repeatable and sustainable for more than four months.Likewise, stable cell lines containing shRNA target sequences displayeda significant delay to onset of tumor growth as compared to empty vectoror scrambled sequence controls. This result was also repeatable. Afterabout one month, subcutaneous tumors began to form from thelentivirally-infected shRNA stable cells. Once they appeared, thesetumors progressed at similar rate to their empty vector and scramblesequence controls. This is likely due to the absence of selection mediain vivo. For confirmation, in vitro passaging of cells in low doseselection media was done and yielded return of cadherin-11 expression tothat of controls within six to eight weeks of culture. These data, alongwith the functional assays, show cadherin-11 is necessary for tumorgrowth of breast cancer cells.

The mice (female athymic mice used prior to 20 weeks of age) weremaintained at the Department of Comparative Medicine Animal Facility ofGeorgetown University Medical Center (Washington, D.C.). Experimentalprocedures and handling were performed in a laminar flow hood for nudemice. For xenografts, 1-2×10⁶ siRNA pooled or shRNA lentiviral stablecells, previously described, were injected s.c. into one of four mammaryfat pads such that control and RNAi-expressing cells were present in thesame animal. Tumors were detected by palpation and measured twice weeklywith calipers, and tumor volume was deduced using the formula D1×D2×D3,where D1 is the length, D2 is the width, and D3 is the depth of thetumor. Experiments were repeated three times for all cell lines.

Example 10 Microarray Analysis

Microarray analysis has become a tool for determining potential geneticsignatures of various disease profiles. In cancer, microarray has beenused to analyze genetic differences regarding hormone status, cellularsubtype, metastasis and recurrence, patient prognosis, and treatmentresponse among a multitude of malignancies, tumor cells and cellularmanipulations. Much of this data is available for furtherinterpretation, leading to additional scientific conclusions from thesame data sets. As such, microarray analysis was performed using thesiRNA pooled stable cells to determine which genes are significantlyaltered upon depletion of cadherin-11 in aggressive breast cancer cells.The information generated from that analysis was further compared withexisting data sets examining basal-like cancer phenotype, stromalcontribution to tumor progression, metastasis, and glioblastomamultiforme. Cadherin-11 was significantly upregulated in Basal B cancercells, poor prognosis breast and brain carcinomas and breast tumorstroma as compared with normal mammary stroma.

Example 11 Inhibition of Cadherin-11 Function

Upon initial screening of inhibitors as described in Example 3, Compound9 (Sd-Cad11-037) and Compound 10 (Sd-Cad11-073) were found tofunctionally block cadherin-11 at doses of nanomolar range. These twopharmacophores were further refined and screened again to maximizesolubility and then retested using various in vitro assays. Compound 1(Sd-Cad11-133, also referred to as sd-133) significantly blockedcadherin-11 function regarding proliferation, colony growth, andinvasion at 100 nanomolar range (FIGS. 3-8 and 9B). In addition, theinhibitor appears to be specific for cadherin-11, as it fails to blockproliferation and invasion in MDA-MB-435 melanoma cells or MCF7 breastcancer cells at 1 and 10 μM concentrations. The data also implies thatgrowth phenotypes in PC-3 prostate cancer cells may also be partiallyinhibited, further confirming that cadherin-11 is being successfullytargeted by the agent. Finally, it was also observed that the compoundwas not cytotoxic up to a 100 μM dosage in vitro, as well as a pilotstudy in nude mice.

Example 12 Cadherin-11 Regulated Tumor Growth and Progression in PoorPrognosis Cancer

Materials and Methods

Cell Culture and Generation of Stable Cell Lines. Parental MDA-MB-231breast cancer cell lines, PC-3 prostate cancer cell lines, and LN229glioblastoma cell lines were acquired from Lombardi Comprehensive CancerCenter Tissue Culture Shared Resource (Washington, D.C.), and generatedstable cell lines were maintained in DMEM (Invitrogen; Carlsbad, Calif.)supplemented with 5% fetal bovine serum (FBS) as described in Example 1.siRNA vectors were synthesized using the Silencer™ siRNA ConstructionKit (Ambion; Foster City, Calif.) and co-transfected with hygromycinB-resistant vector or vector alone into MDA-MB-231 using Fugene (RocheDiagnostics; Indianapolis, Ind.). siRNA stable lines were created usinganti-sense (5′-AACAGCGTGGATGTCGATGACCCTGTCT C-3′) (SEQ ID NO: 1) andsense (5′-AAGTCATCGACATCCACGCTGCCTGTCTC-3′) (SEQ ID NO: 2) sequences totarget cadherin-11 (CDH11) wt. Clones were selected using lmg/mLhygromycin B and maintained using 0.5 mg/mL. The entire transfectionprocess was repeated three times consecutively. Following finalselection, five clones were randomly selected and pooled to createstable cell lines.

shRNA stable cell lines were created using MISSION® shRNA lentiviraltransduction particles (Sigma-Aldrich; St. Louis, Mo.) directed againsthuman cadherin-11 (CDH11). Two separate shRNA sequences targeting thesame cadherin-11 (CDH11) region were used to infect MDA-MB-231 breastcancer cells, PC-3 prostate cancer cells, and LN229 glioblastoma cells.Clones were selected with 15 μg/mL puromycin and maintained in 10 μg/mL.Stable cell lines studied were selected based upon cadherin-11 (CDH11)protein expression as measured by Western blot analysis.

Western Blot and Immunocytochemistry. Western blots andimmunocytochemistry were performed as described in Examples 2 and 4using monoclonal antibodies to cadherin-11 (CDH11) (5B2H5: Zymed) andGAPDH (Research Diagnostics; Concord, Mass.), polyclonal β-catenin, andperoxidase, fluorescein (Kirkegaard and Perry Laboratories, Inc.;Gaithersburg, Md.) or Texas Red-conjugated (Jackson ImmunoResearchLaboratories, Inc.; West Grove, Pa.) secondary antibodies.

Proliferation Assays

Crystal Violet Assays: Cells were plated in triplicate at four separatedensities and grown in DMEM with 5% FBS for five days. Cells werestained with crystal violet on days 1, 3, and 5 after plating, asdescribed in Example 5. Absorbance was read at 630 k using a BioRadUltramark Microplate Imaging System with Microplate Manager 5.1software.

Luminescence: Cells were plated in triplicate in white-walled dishes(Wallac; Waltham, Mass.) and grown in DMEM with 5% FBS for five days. Atday 5, cells and a blank were resuspended in Cell-Titer-Glo LuminescenceReagent (Promega; Madison, Wis.), incubated for 20 minutes at roomtemperature, and measured using a Wallac Victor 2, 1420 Multilabelcounter.

Soft Agar Assays. Cells (5,000) were plated in 0.3% agar layered on topof 0.6% agar in 35-mm² plates. After 2 weeks, the colonies were countedin an Omnicon 3600 automated colony counter (BioLogics, Inc.; Manassas,Va.) and visualized using a SMZ-1500 stereoscope (Nikon; Tokyo, JP).Confirmation assays were completed in 24-well dishes and analyzed usingCell-Titer-Glo Reagent (see proliferation assays).

Wound Healing and Matrigel Outgrowth Assays. Cells were grown toconfluency in DMEM supplemented with 5% FBS and washed with 1×PBS.Vertical scrape wounds were made in each well (24-well plate) with a 10μL pipette tip and then the growth medium was replaced. Phase imageswere recorded immediately following scraping and every hour using 10×objective (Nikon Eclipse TE-300 inverted microscope with motorized stageand CO₂-regulated chamber, controlled by the Multidimensional Analysistool of Metamorph Image Acquisitions software; Tokyo, JP). Migrationdistances were manually calculated by caliper scaling of wound widthusing Metamorph tracking module.

Matrigel Outgrowth Assays: Cells (5,000 cells/100 μl medium) were platedatop 150 μL layer of Matrigel (BD Biosciences; San Jose, Calif.) induplicate in 12-well glass-bottom dishes (MatTek; Ashland, Mass.) andincubated for 30 minutes at 37° C. Growth medium (1 mL) was gently addedto each well. Growth was visualized using a 5× objective on AH2 Vanoxinverted microscope (Olympus; Tokyo, JP).

Animal Studies. Female Athymic Nude Mice were Purchased from CharlesRiver

Laboratories (Wilmington, Mass.) and used prior to 20 weeks old. Forxenografts, 1-2×10⁶ stable cells were injected s.c. into one of fourventral side mammary fat pads such that each animal possessed controland RNAi-expressing cells. Tumors were measured with calipers twice perweek and the tumor volume was calculated using formula D1×D2×D3(D1=length, D2=width, D3=depth of tumor). Experiments were repeatedthree times for all cell lines (total 26 mice across all studies).

Statistical Methods. Student's t-test determined statisticalsignificance for in vitro comparisons. Survival, relapse, and tumorlatency analyses were plotted using Kaplan-Meier methods and comparedusing log-rank tests. For all statistical analyses, p<0.05 wasconsidered significant. Figure columns and bars represent meancomparisons and SEM, respectively.

Microarray Analysis and Data Processing. Total RNA was isolated fromknockdown and control cells [3 controls (1B), 2 each (4A and 6Aknockdown)] using Trizol reagent (GIBCO BRL Life Technologies; Carlsbad,Calif.) and purified using RNeasy Mini Kit (Qiagen; Germantown, Md.).Preparation of in vitro transcription (IVT) products, oligonucleotidearray hybridization, and scanning were performed (Affymetrix, Inc.;Santa Clara, Calif.). The integrity and quality of produced cRNA metrecommended specifications for use with Human Genome U133-A arrays.Probe set-based gene expression measurements were generated fromquantified Affymetrix image files (.CEL) using the RMA algorithm fromBioConductor in BRB-Array Tools (NCI; Bethesda, Md.). Probe sets wereannotated (Unigene; Fairfield, N.J.), gene expression values centered,and data organized using hierarchical clustering forsimilarity/difference in gene expression across samples. Analyses wererestricted to genes differentially expressed in pair-wise comparisonsbetween treated and untreated samples (p<0.01), resulting in 236 probesets corresponding to 187 unigenes. Agglomerative clustering withcomplete linkage was applied to probe sets and samples (uncenteredPearson's correlation), and clusters visualized with Java TreeView.

Computational Methods. The energy minimized x-ray crystal structure ofthe EC1 domain of cadherin-11 (CDH11) dimer (PDB: 2A4C) was used for allthe computational modeling. Flexible receptor structures were generatedby Molecular dynamics (MD) simulations, performed with adistant-dependent dielectric constant using the Sander module of AMBER9.0 with the PARM98 force-field parameter (all other parameters set todefault). Docking simulations were done with FlexX module of Sybyl 8.0(Tripos Inc.; St. Louis, Mo.), with parameters set to default (number ofligand conformations was set to 90) to provide a large window offlexibility to select the best fit ligand in the ORI method.3D-pharmacophore models were developed using the UNITY module of Sybyl8.0 (Tripos Inc.; St. Louis, Mo.). For the generation of flexiblereceptor conformations, molecular dynamics (MD) simulations were carriedout at one nanosecond intervals, and several instantaneous low and highenergy conformations were selected. These conformations were thenclustered, and five representative conformations selected. In thepharmacophore strategy, several models were developed within thetryptophan binding site of the cadherin-11 EC1 domain. Therepresentative structures obtained from the ensembles were used todevelop dynamic pharmacophore models, in which the relative positions ofthe donor, acceptor, hydrophobic, and negative/positive centers of theresidues were defined with various macro, spatial and distanceconstraints features with excluded volume spheres. Induced fit effectand virtual binding affinity was predicted from the 250 picosecond freeenergy simulations. MM-PBSA free energy method was used to predict theabsolute binding affinities. Three separate simulations were carried outfor ligand alone, receptor alone, and the complex. In the MM-PBSAmethod, the average total free energy of the system (AG) is evaluated asfollows:ΔG _(bind) =<ΔG _(complex) >−<ΔG _(protein) >−<ΔG _(ligand) −; ΔG_(bind) =<ΔE _(MM) >+<ΔG _(PB) >+<ΔG _(SA) >−<TΔS>where ΔG_(PB)=polar solvation energy in continuum solvent computed usinga finite-difference Poisson-Boltzmann (PB) model and ΔG_(SA)=nonpolarsolvation energy, obtained from the solvent-accessible surface area(SASA). The non-polar contribution to the solvation free energy wasapproximated with the SASA model, where surface tensioncoefficient=0.00202 kcal/mol Å² and β=0.92 kcal/mol. The SASA wasestimated with a 1.4 Å solvent-probe radius as implemented in SanderModule of AMBER9.0. ΔE_(MM) denotes the sum of molecular mechanical (MM)energies of the molecules from internal, electrostatic, and van derWaals energies. The last term in equation is the solute entropy i.e.conformational free energy and can be estimated by normal-mode analysis.

FIG. 9A is a schematic of the small molecule screening strategy usedherein. Specifically, a total of 7,073 compounds were obtained uponscreening of five pharmacophore models with an in-house database of over30 million compounds (collected from more than 150 chemical companies,and literature resources). Subsequently, 16 subsets of compounds wereselected using Physical Chemical Filtering by Rule of Five, druglikeness, and commercial availability. For the small molecule dockingsimulations, some 157,217 pre-selected compounds (filtered fordrug-likeness and commercial availability) were screened against fiverepresentative flexible conformations, including the rigid x-raystructure, and a large window of 4,546 compounds were selected based onranking with an arbitrary energy cut-off of 25 kcal/mol. In certaincases, compounds were returned possessing a large binding free energythat would not necessarily be expected to be active. Therefore, to avoidthis computational artifact, and also to reduce the large dataset, theOptimal Reference Interaction (ORI) method was implemented. Theprinciple idea of the ORI maintains that ligands that interact with thesame binding site residues as the reference molecule (in this case thetryptophan-containing pocket amino acids) are more likely to be active.The nature of the interactions and their interacting residue motifs weregiven as input to the ORI algorithms, and yielded 138 compounds thatperfectly matched the criteria. Of the 154 compounds filtered from bothstrategies, the 29 most promising candidates were subjected to freeenergy simulations at 100 picosecond intervals, taking intoconsideration the induced fit effect, which accounts for conformationflexibility both before and after binding/docking simulations. In theORI method, as well as for pharmacophore generation, all criticalinteractions between tryptophan and the cadherin-11 EC1 domain wereincluded, except E87 and D27 as they showed high flexibility whenexposed to solvent.

Results

Cadherin-11 Expression is Inversely Related to Relapse and Survival inSeveral Cancers. Published expression array datasets examining a varietyof tumor types were compared (FIG. 10). It was found that highcadherin-11 expression was significantly associated with poor outcome inbreast and prostate cancer, papillary renal cell carcinoma, multiplemyeloma and glioblastoma. In breast cancer cell lines, cadherin-11expression was almost completely restricted to basal-B type cells.

Cadherin-11 Regulates Proliferation and Anchorage-Independent Growth ofBreast and Prostate Cancer Cells. These analyses show cadherin-11 as auseful diagnostic marker. Endogenous cadherin-11 expression inMDA-MB-231 breast and PC-3 prostate cancer cells was knocked down bystable transfection of siRNA or infection of shRNA (see Materials andMethods). Cadherin-11 expression was determined in resulting stable celllines by quantitative RT-PCR and Western blot (FIG. 11A). Two pooledsiRNA-targeted lines and one clonal line from each of two shRNA-targets(54333 and 54334) were selected. Additionally, 54333 and 54334 shRNAviral supernatants and an empty vector control were used to createstable cadherin-11-targeted PC-3 prostate cancer cells (FIG. 11A). InPC-3 cells, 54333 shRNA infection did not significantly reducecadherin-11 and was subsequently used as a control in some experiments.Although expression was significantly reduced, cadherin-11 knockdowncell lines show similar morphology to parental MDA-MB-231 cells (FIG.17A). β-catenin expression remained relatively constant and its locationwas retained at the cell membrane in the absence of cadherin-11.

Cell adhesion affects cellular proliferation throughout development andin tumorigenesis, and depletion of endogenous cadherin-11 in smoothmuscle cells significantly inhibits their proliferation. Cadherin-11knockdown significantly decreased proliferation in MDA-MB-231 and PC-3cancer cells (FIGS. 11B, 17B, and 17C). Anchorage-independent growth ofbasal-B type MDA-MB-231 breast and PC-3 prostate cancer cells was alsosignificantly reduced following cadherin-11 knockdown (FIG. 11C).

Cadherin-11 Alters Migratory and Invasive Potential of Breast andProstate Cancer Cells. Reduction of cadherin-11 in MDA-MB-231 breast andPC-3 prostate cancer cells significantly decreased their migration inwound healing assays (FIG. 12A). The phenotype of cadherin-11 knockdowncells in a 3-dimensional matrix was next examined. MDA-MB-231 breast andPC-3 prostate cancer cells cultured on Matrigel basement membrane-likematrix form branched networks within one week. It was observed thatcontrol cells containing either empty vector or scrambled targetsequence also form networks throughout Matrigel within 7 days (FIG.12B). Cadherin-11 depleted cells failed to form networks their firstweek in culture, however, over the ensuing week, the cells formednetworks that were indistinguishable from controls. Prostate cancercells displayed a similar delayed network formation phenomenon (FIG.12B).

Cadherin-11 is Required for Subcutaneous Tumor Growth In Vivo.MDA-MB-231 cells readily form tumors in nude mice. Stable control orknockdown cells were subcutaneously injected into athymic nude mice andtumor growth assessed twice weekly with calipers for 6 weeks. Cellscontaining siRNA targeting cadherin-11 completely failed to form tumorsin nude mice, whereas the empty vector controls formed subcutaneoustumors (FIG. 13). This experiment was repeated several times and none ofthe 26 cadherin-11 knockdown cell injections resulted in a significanttumor. Likewise, stable cell lines containing shRNA-targeted sequencesdisplayed significant delay to onset of tumor growth compared to emptyvector or scrambled sequence controls. However, after about one month,subcutaneous tumors began to form from injections of onelentivirally-infected shRNA stable cell (FIG. 13). Once palpable, thesetumors progressed at a similar rate to empty vector and scrambledcontrols. However, in vitro Western blot results indicate these cellsbegan to re-express cadherin-11 at that time, and in the absence ofselection media. These data, along with functional assays in vitro, showthat cadherin-11 is necessary for tumor growth in MDA-MB-231 breastcancer cells. They further show that cadherin-11 provides a viabletherapeutic target in epithelial cancers with increased cadherin-11expression.

Cadherin-11 Knockdown Alters the Expression of Genes Associated withPoor Prognosis Malignancies. Microarray analysis was performed usingAffymetrix U133-A arrays to determine genes significantly altered upondepletion of cadherin-11 in aggressive breast cancer cells (seeMaterials and Methods). Empty vector controls (RNAi 1B) were comparedwith two different stable knockdown cell lines (RNAi 4A and 6A) on threeseparate occasions. An inter-sample comparison was performed separatelyamong the controls and then the four cadherin-11 (CDH11) depletedsamples, and outlying genes differing greater than 1.5 fold amongrespective groups were excluded from further analyses (FIG. 14A).Resulting control and knockdown gene sets were compared to one anotherusing a significance minimum of p<0.01, yielding 187 differentiallyexpressed genes comprising gene ontology classes including celladhesion, signaling and movement, cancer, connective tissue andinflammatory diseases (FIG. 14B). Many of these genes were associatedwith poor prognosis cancers and the stromal cell signature predictive ofpoor outcome in breast cancer patients. Twenty-four genes were common tothe Wang dataset examining breast cancer relapse (FIG. 14C). Multiplecellular adhesion genes (COL5A1, ITGB3, and THBS1) are affected bycadherin-11 depletion in breast cancer, along with reduction of knownEMT markers (SMAD6 and SNAI2) and metalloproteinase family genes (ADAMand TIMP3) associated with aggressive cancers and metastasis.Additionally, cadherin-11 reduction significantly increases putativetumor suppressor genes NOL7 and PRSS3. Together these data indicate thatcadherin-11 regulates expression of genes important in basal-B breastcancer cells, along with poor prognosis malignancies of the breast,prostate, brain, plasma cell, and kidney.

Small Molecule Cadherin-11 Inhibitors Specifically Inhibit Cadherin-11Function In Vitro. Cadherin-11 association with certain poor prognosiscancers, proliferation of basal-type breast cancer cells, andtumorigenesis in mice make it a viable therapeutic target for thesemalignancies. The crystal structure of cadherin-11 reveals uniquebinding pockets as potential sites for interference of cell-celladhesion (FIG. 1B). A computer-based method of structural modeling wasused to predict conformations capable of binding these specifichydrophobic pockets. The ectodomain1 (EC1) dimer adhesive interface isformed by exchange of N-terminal β strands between two cadherin-11molecules. The dimer interface has a large hydrophobic region (unique totype II cadherins) with two conserved tryptophan residues. It wasreasoned that a small molecule blocking cadherin-11 EC1 dimer formationwould potentially inhibit cadherin-11 function. This structure was usedto base molecular simulations and produce pharmacophores designed toblock one or both of the two adjacent regions (P1 and P2) predictednecessary for cadherin-11 function in cell-cell adhesion. Threein-silico strategies were implemented: 1) generation of flexiblereceptor conformations, 2) receptor-based dynamic pharmacophorescreening and 3) small molecule docking simulations. The 29 mostpromising candidates identified by in silico screen were subjected tofree energy simulations at 100 picosecond intervals, taking intoconsideration the induced fit effect, which accounts for conformationflexibility both before and after binding/docking simulations. Allcritical interactions between tryptophan and the cadherin-11 EC1 domainwere included, except E87 and D27 which showed high flexibility uponsolvent exposure. These 29 compounds were purchased commercially andtested. Many of the compounds initially screened inhibited cadherin-11function at 10 μM range, attesting to the in silico screeningefficiency. Three compounds, Compound 1 (Sd-133), Compound 9 (Sd-037),and Compound 10 (Sd-073), were effective in nanomolar ranges. Compound 1significantly inhibited MDA-MB-231 cell proliferation, colony growth,and invasion at 100 nM (FIG. 15A-C). The inhibitor failed to alterproliferation or invasion in MDA-MB-435 melanoma cells (expressingN-cadherin) and MCF7 breast cancer cells (expressing E and P-cadherin)at 1 μM and 10 μM concentrations, indicating specificity forcadherin-11-expressing cells (FIG. 15A-C). The potency of Compound 1likely stems from its shape and moderate structural flexibility,enabling it to accommodate to and bind tightly within the tryptophanbinding pocket. Though this pocket is largely hydrophobic, a network ofhydrogen bonds between Compound 1 and R23, H25, P88, S90 confersspecificity and rigid binding. Hydrophobic interaction of Compound 1with F7, L24, S26, Y37, A75, A77, E87, S90, and F92 may also contributeto its action. Furthermore, the mobility of the water molecule locatednear S90 allows possible adjustment of its position to form hydrogenbonds with the inhibitors. Two other potent inhibitors, Compound 9 and10, have similar interactions with the tryptophan pocket. The watermediated H-bond is observed with all three inhibitors after 500picosecond MD simulations run to include induced fit effects. All threeinhibitors compete for tryptophan binding and interact with the sameresidues including the water molecule formed by the two tryptophans.Superimposition of Compounds 1, 9, and 10 within the tryptophan pocketclearly shows the hydrophobic moieties of these inhibitors occupy thesame space as that of hydrophobic tryptophans. Collectively, these datashow cadherin-11 is important for tumor progression in cancers,including poor prognostic cancers, expressing it.

Example 13 Cell Aggregation Assay

Cell aggregation assays were performed on L-cells withstably-transfected empty vector or cadherin-11. The cells were seededand grown overnight, trypsinized with additional EDTA, resuspended inDMEM with 20% FBS, and counted. The cells were spun down and resuspendedin DMEM containing no treatment, 0.5 mM EDTA, 0.25 mM EDTA, 0.1 mM EDTA,or cadherin-11 inhibitors including 1 TM of Compound 1 (Sd-133), 1 TM ofCompound 2 (Sd-133A), 1 TM of Compound 3 (Sd-133B), 1 TM of Compound 11(Sd-12), 1 TM of Compound 12 (Sd-48), 1 TM of Compound 17 (Sd-20), 1 TMof Compound 18 (Sd-51), 1 TM of Compound 19 (Sd-22), or 1 TM of Compound20 (Sd-23). The cells were allowed to recover for one hour and were thenput into uncoated 12 well plates and shaken for one hour at 100 rpm at2.25×105 cells/mL. The cells were then counted using Microsizer CoulterCounter (Beckman Coulter, Inc; Brea, Calif.). Counts over 20 uM inlength were considered aggregates, while counts below 20 uM wereconsidered as single cells. The counts were confirmed by manualcounting. As shown in FIGS. 16A and 16B, under these conditions, thecadherin-11 cells treated with at least Compounds 2 and 3 showed adecrease in aggregate formation, while the empty vector transfectedcells remained stable.

Example 14 In Vivo Toxicity Data

Female Balb/c mice, 8-12 weeks old, were obtained from the NationalCancer Institute (Bethesda, Md.). A stock solution of 200 mg/ml ofCompound 1 was prepared with a 1:1 ratio of DMSO and PEG. The workingsolution was diluted with PEG. Compound 1 (Sd-133) was administered at aconstant volume (0.01 ml/1 g body weight) over the range of doses to betested by varying the concentration of the dosing preparation accordingto the OECD Acute Toxicity-Up-and Down Procedure. A test dose wasadministered to one animal by IP injection and the animal was observedfor 14 days. Observations included toxicity onset time, symptoms,duration and the time elapsed for recovery or death. Based on the study,the LD50 of Compound 1 was estimated at 2000 mg/kg.

Example 15 Cadherin-11 is Required for the Growth and Invasion ofGlioblastoma Cell Line LN229

Cadherin-11 or N-cadherin was knocked down in LN229 cells using shRNAaccording to methods described in Example 12. A significant reduction incadherin-11 and N-cadherin protein 48 hours after infection withlentivirus containing shRNA was shown (FIG. 18A). Knockdown ofcadherin-11 reduces in vitro invasion (FIG. 18B) and growth of LN229cells (FIG. 18C). These data show that cadherin-11 expression inglioblastoma cells is required for their continued growth and invasionin vitro. In the three tumor types in which cadherin-11 is associatedwith poor prognosis, including basal-like breast and prostate cancersand glioblastoma, its expression is important for their growth andinvasion.

Example 16 In Vivo Antibody Treatment

Mice bearing MDA-231, LN229, or PC3 xenografted tumors will be injectedIP with 50 μg/kg of a cadherin-11 antibody or control IgG at weeklyintervals for 60 days. Tumor growth will be monitored and the effects ofthe cadherin-11 antibody will be compared to animals bearing MDA435 cellxenografts expressing N-cadherin.

What is claimed is:
 1. A compound of the following formula:

or a pharmaceutically acceptable salt thereof, wherein: R⁴, R⁵, R⁶, R⁹,R¹⁰, and R¹¹ are each independently selected from hydrogen, halogen,hydroxyl, substituted or unsubstituted alkoxy, substituted orunsubstituted amido, substituted or unsubstituted amino, substitutedcarbonyl, substituted or unsubstituted alkyl, unsubstituted orunsubstituted alkenyl, substituted or unsubstituted alkynyl,unsubstituted heteroalkyl, unsubstituted or unsubstituted heteroalkenyl,substituted or unsubstituted heteroalkynyl, substituted or unsubstitutedcycloalkyl, unsubstituted or unsubstituted cycloalkenyl, substituted orunsubstituted cycloalkynyl, substituted or unsubstitutedheterocycloalkyl, unsubstituted or unsubstituted heterocycloalkenyl,substituted or unsubstituted heterocycloalkynyl, substituted orunsubstituted aryl, and substituted or unsubstituted heteroaryl; and R¹³is halogen, hydroxyl, substituted or unsubstituted alkoxy, substitutedor unsubstituted amido, substituted or unsubstituted amino, substitutedor unsubstituted alkyl, unsubstituted or unsubstituted alkenyl,substituted or unsubstituted alkynyl, unsubstituted heteroalkyl,unsubstituted or unsubstituted heteroalkenyl, substituted orunsubstituted heteroalkynyl, substituted or unsubstituted cycloalkyl,unsubstituted or unsubstituted cycloalkenyl, substituted orunsubstituted cycloalkynyl, substituted or unsubstitutedheterocycloalkyl, unsubstituted or unsubstituted heterocycloalkenyl,substituted or unsubstituted heterocycloalkynyl, substituted orunsubstituted aryl, or substituted or unsubstituted heteroaryl, whereinat least one of R⁵ and R¹⁰ is hydroxyl.
 2. The compound of claim 1,wherein R⁵ is hydroxyl.
 3. The compound of claim 1, wherein R⁶ ischloro.
 4. The compound of claim 1, wherein R¹⁰ is hydroxyl.
 5. Thecompound of claim 1, wherein R¹³ is hydroxyl or chloro.
 6. The compoundof claim 1, wherein the compound is:

or a pharmaceutically acceptable salt thereof.
 7. The compound of claim1, wherein the compound is:

or a pharmaceutically acceptable salt thereof.
 8. The compound of claim1, wherein the compound is:

or a pharmaceutically acceptable salt thereof.
 9. The compound of claim1, wherein the compound is:

or a pharmaceutically acceptable salt thereof.
 10. A pharmaceuticalcomposition comprising a compound of claim 1 and a pharmaceuticallyacceptable carrier.
 11. A compound of the following formula:

or a pharmaceutically acceptable salt thereof.